0001144204-18-059353.txt : 20181113 0001144204-18-059353.hdr.sgml : 20181113 20181113160629 ACCESSION NUMBER: 0001144204-18-059353 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marker Therapeutics, Inc. CENTRAL INDEX KEY: 0001094038 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880277072 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37939 FILM NUMBER: 181177954 BUSINESS ADDRESS: STREET 1: 5 WEST FORSYTH STREET STREET 2: SUITE 200 CITY: JACKSONVILLE STATE: FL ZIP: 32202 BUSINESS PHONE: (904) 516-5436 MAIL ADDRESS: STREET 1: 5 WEST FORSYTH STREET STREET 2: SUITE 200 CITY: JACKSONVILLE STATE: FL ZIP: 32202 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC. DATE OF NAME CHANGE: 20170629 FORMER COMPANY: FORMER CONFORMED NAME: TAPIMMUNE INC DATE OF NAME CHANGE: 20070628 FORMER COMPANY: FORMER CONFORMED NAME: GENEMAX CORP DATE OF NAME CHANGE: 20020718 10-Q 1 tv506096_10q.htm 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2018

Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____.

Commission File Number: 001-37939

MARKER THERAPEUTICS, INC.

(Name of registrant in its charter)

DELAWARE		45-4497941
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

5 West Forsyth Street, Suite 200 Jacksonville, FL		32202
(Address of principal executive offices)		(Zip Code)

904-516-5436
(Issuer's telephone number)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “accelerated filer”, “large accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act (check one):

¨	Large accelerated filer	¨	Accelerated filer
x	Non-accelerated filer	x	Smaller reporting company
		¨	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of November 8, 2018, the Company had 45,370,695 shares of common stock issued and outstanding.

		Page

PART I – FINANCIAL INFORMATION		1

Item 1.	Financial Statements (Unaudited)	1

	Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017	1

	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017	2

	Condensed Consolidated Statement of Stockholders' Equity for the nine months ended September 30, 2018	3

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017	4

	Notes to Condensed Consolidated Financial Statements	5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	12

Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	22

Item 4.	Controls and Procedures.	22

PART II – OTHER INFORMATION		23

Item 1.	Legal Proceedings.	23

Item 1A.	Risk Factors.	23

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	23

Item 3.	Defaults Upon Senior Securities.	23

Item 4.	Mine Safety Disclosures.	23

Item 5.	Other Information.	23

Item 6.	Exhibits.	23

Signatures		25

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements

MARKER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

	September 30, 2018			December 31, 2017

ASSETS
Current assets:
Cash	$	4,294,271		$	5,129,289
Prepaid expenses and deposits		96,967			51,150
Total current assets		4,391,238			5,180,439
Total assets	$	4,391,238		$	5,180,439


LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	3,588,771		$	1,508,312
Warrant liability		107,000			9,000
Promissory note		5,000			5,000
Total current liabilities		3,700,771			1,522,312
Total liabilities		3,700,771			1,522,312

COMMITMENTS AND CONTINGENCIES

Stockholders' equity:
Preferred stock - $0.001 par value, 5 million shares authorized at September 30, 2018 and December 31, 2017, respectively
Series A, $0.001 par value, 1.25 million shares designated, 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively		-			-
Series B, $0.001 par value, 1.5 million shares designated, 0 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively		-			-
Common stock, $0.001 par value, 41.7 million shares authorized, 13.8 million and 10.6 million shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively		13,845			10,616
Additional paid-in capital		171,221,851			161,067,538
Accumulated deficit		(170,545,229	)		(157,420,027	)
Total stockholders' equity		690,467			3,658,127
Total liabilities and stockholders' equity	$	4,391,238		$	5,180,439

See accompanying notes to these unaudited condensed consolidated financial statements.

MARKER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the three months ended						For the nine months ended
	September 30,						September 30,
	2018			2017			2018			2017
Revenues:
Grant income	$	-		$	183,064		$	205,994		$	183,064
Total revenues		-			183,064			205,994			183,064
Operating expenses:
Research and development		1,877,260			1,623,302			5,303,647			3,815,119
General and administrative		2,551,146			2,549,272			7,202,036			5,167,582
Total operating expenses		4,428,406			4,172,574			12,505,683			8,982,701
Loss from operations		(4,428,406	)		(3,989,510	)		(12,299,689	)		(8,799,637	)
Other income (expense):
Change in fair value of warrant liabilities		40,000			4,000			(98,000	)		8,500
Debt extinguishment gain		-			-			-			492,365
Net loss	$	(4,388,406	)	$	(3,985,510	)	$	(12,397,689	)	$	(8,298,772	)

Net loss per share, Basic and Diluted	$	(0.32	)	$	(0.39	)	$	(1.03	)	$	(0.91	)
Weighted average number of common shares outstanding		13,733,406			10,219,138			12,082,176			9,081,678

See accompanying notes to these unaudited condensed consolidated financial statements.

MARKER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

(UNAUDITED)

											Total
	Common Stock				Additional Paid-			Accumulated			Stockholders'
	Shares		Par value		in Capital			Deficit			Equity
Balance at January 1, 2018		10,615,724	$	10,616	$	161,067,538		$	(157,420,027	)	$	3,658,127
Issuance of common stock in private placement		1,300,000		1,300		3,118,700			-			3,120,000
Stock options exercised for cash		10,416		10		18,115			-			18,125
Stock warrants exercised for cash		1,496,881		1,497		4,342,674			-			4,344,171
Stock warrants cashless exercised		215,336		215		(215	)		-			-
Stock-based compensation		206,446		207		1,947,526			-			1,947,733
Fair value of repriced warrants as inducement		-		-		727,513			(727,513	)		-
Net loss		-		-		-			(12,397,689	)		(12,397,689	)
Balance, September 30, 2018		13,844,803	$	13,845	$	171,221,851		$	(170,545,229	)	$	690,467

See accompanying notes to these unaudited condensed consolidated financial statements.

MARKER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the nine months ended
	September 30,
	2018			2017
Cash Flows from Operating Activities:
Net loss	$	(12,397,689	)	$	(8,298,772	)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities		98,000			(8,500	)
Stock-based compensation		1,947,733			2,332,915
Debt extinguishment gain		-			(492,365	)
Changes in operating assets and liabilities:
Prepaid expenses and deposits		(45,817	)		(26,381	)
Accounts payable and accrued expenses		2,080,459			532,122
Net cash used in operating activities		(8,317,314	)		(5,960,981	)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs		3,120,000			5,408,343
Proceeds from exercise of stock warrants, net of offering costs		4,344,171			619,623
Proceeds from exercise of stock options		18,125			-
Repurchase of common stock to pay for employee withholding taxes		-			(310,493	)
Net cash provided by financing activities		7,482,296			5,717,473
Net decrease in cash		(835,018	)		(243,508	)

Cash at beginning of period		5,129,289			7,851,243
Cash at end of period	$	4,294,271		$	7,607,735

	For the nine months ended
	September 30,
	2018		2017
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	$	727,513	$	622,042
Stock warrants cashless exercised	$	215	$	-

See accompanying notes to these unaudited condensed consolidated financial statements.

MARKER THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2018

(Unaudited)

Note 1: Nature of Operations

Marker Therapeutics, Inc., a Delaware corporation formerly known as TapImmune, Inc. (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of innovative cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, and novel peptide-based vaccines for the treatment of breast and ovarian cancers. The Company’s cell-based immunotherapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells recognizes multiple tumor targets to produce broad spectrum anti-tumor activity. Because the Company does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with potentially meaningful clinical benefit. As a result, the Company believes its portfolio of T cell therapies has a potentially compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. In addition, the Company’s legacy Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu program (TPIV100/110) are in a combined five Phase II clinical trials. In parallel, the Company has been working on a proprietary nucleic acid-based antigen expression technology named PolyStart™ to improve the ability of the immune system to recognize and destroy diseased cells. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018 in connection with the Marker Transaction.

On October 17, 2018, the Company completed its previously announced business combination with Marker Cell Therapy, Inc., formerly known as Marker Therapeutics, Inc., a privately-held Delaware corporation (“Marker Cell”), in accordance with the terms of an Agreement and Plan of Merger and Reorganization dated as of May 15, 2018 (the “Merger Agreement”) by and among the Company, Timberwolf Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Marker. On October 17, 2018, pursuant to the Merger Agreement, Merger Sub was merged with and into Marker Cell (the “Merger”), with Marker Cell being the surviving corporation and becoming a wholly-owned subsidiary of the Company. In connection with the Merger, the Company changed its name to Marker Therapeutics, Inc. and Marker Cell changed its name to Marker Cell Therapy, Inc. At the effective time of the Merger, the former Marker Cell stockholders received (i) an aggregate of 13,914,255 shares of the Company’s common stock which equaled the number of shares of the Company’s common stock issued and outstanding immediately prior to the effective time of the Merger, and (ii) an aggregate of 5,046,003 warrants which equaled the number of the Company’s warrants and stock options issued and outstanding immediately prior to the effective time of the Merger.

NOTE 2: Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2018 or for any future interim period. The condensed consolidated balance sheet at September 30, 2018 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2017, and notes thereto included in the Company’s annual report on Form 10-K filed on March 23, 2018 and the Company’s Form 8-K and Form 8-K/A filed on October 30, 2018 and October 26, 2018, respectively.

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

As of September 30, 2018, the Company had cash of approximately $4.3 million. On October 17, 2018, concurrent with the completion of the merger with Marker Cell, the Company issued shares of its common stock to certain accredited investors in a private placement transaction for proceeds of $61.8 million, net of banker fees, pursuant to the terms of the Securities Purchase Agreement.

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

Note 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 23, 2018.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Recent Accounting Pronouncements Adopted in the Year

Compensation-Stock Compensation

In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company adopted ASU 2017-09 on January 1, 2018; the adoption of ASU 2017-09 did not have a material impact on its financial condition or results of operations, as the Company has not had any modifications to share-based payment awards. However, if the Company does have a modification to an award in the future, it will follow the guidance in ASU 2017-09.

Revenue from Contracts with Customers

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue.

Recent Accounting Pronouncements Not Yet Adopted

Accounting for Certain Financial Instruments with Down Round Features

On July 13, 2017, the FASB issued a two-part ASU, No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.

The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.

Improvements to Non-Employee Share-Based Payment Accounting

In June 2018, the FASB issued ASU 2018-07 “Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new standard on its consolidated financial statements.

Leases

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes ASC Topic 840, Leases. ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all the leases with terms greater than twelve months. Based on certain criteria, leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements” that allows entities to apply the provisions of the new standard at the effective date (e.g. January 1, 2019), as opposed to the earliest period presented under the modified retrospective transition approach (January 1, 2017) and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of Topic 842, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. The Company currently expects that most of its operating lease commitments will be subject to the new standard and recognized as operating lease liabilities and right-of-use assets upon its adoption of Topic 842, which will increase the total assets and total liabilities that the Company reports relative to such amounts prior to adoption. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.

SEC Disclosure Update and Simplification

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements.

Note 5: NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of net loss per share:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017
Numerator:
Net loss	$	(4,388,406	)	$	(3,985,510	)	$	(12,397,689	)	$	(8,298,772	)

Denominator:
Weighted average common shares outstanding		13,733,406			10,219,138			12,082,176			9,081,678

Net loss per share data:
Basic and Diluted	$	(0.32	)	$	(0.39	)	$	(1.03	)	$	(0.91	)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended
	September 30,
	2018		2017
Common stock options		439,000		455,000
Common stock purchase warrants		4,625,000		6,517,500
Common stock warrants - liability treatment		27,000		3,500
Potentially dilutive securities		5,091,000		6,976,000

Note 6: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2018 and 2017 is as follows:

	September 30,			September 30,
	2018			2017
Stock price	$	9.05		$	3.01
Exercise price	$	9.72		$	1.20
Contractual term (years)		1.33			0.78
Volatility (annual)		86	%		63	%
Risk-free rate		2	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

Fair value measured at September 30, 2018

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

September 30, 2018

Warrant liability

107,000

Fair value measured at December 31, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2017

Warrant liability

9,000

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2018.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2018:

	Warrant
	Liability
Balance - December 31, 2017	$	9,000
Change in fair value of warrant liability		98,000
Balance – September 30, 2018	$	107,000

Note 7: STOCKHOLDERS’ EQUITY

Common Stock Transactions

Common Stock Purchase Agreement

On May 14, 2018, the Company’s largest stockholder Eastern Capital Limited entered into a Common Stock Purchase Agreement with the Company pursuant to which it purchased 1,300,000 shares of common stock at a price per share of $2.40 providing gross proceeds to the Company of $3.12 million.

Exercise and Repricing of Warrants Held by Existing Institutional Investors

On May 14, 2018, certain institutional holders of outstanding warrants entered into Warrant Exercise Agreements with the Company that provide for an amendment to the exercise price of the warrants being exercised at $2.50 per share. Upon closing of the Warrant Exercise Agreements, such institutional holders immediately exercised warrants for 782,505 shares of common stock providing aggregate proceeds to the Company of approximately $2.0 million.

The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000.

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows:

	Weighted Average Inputs
	Before			After
	Modification			Modification
Exercise price	$	9.93		$	2.50
Contractual term (years)		2.37			2.37
Volatility (annual)		79	%		79	%
Risk-free rate		1.5	%		1.5	%
Dividend yield (per share)		0	%		0	%

Exercise of Stock Warrants

During the nine months ended September 30, 2018, certain outstanding warrants were exercised by warrant holders providing aggregate proceeds to the Company of approximately $2.4 million and resulted in the issuance of approximately 930,000 shares of common stock, which is net of 152,588 warrant shares cancelled due to use of cashless exercise provisions. 215,344 of the stock warrants exercised were exercised on a cashless basis.

Exercise of Stock Options

In January 2018, 10,416 shares of common stock were issued pursuant to stock option exercises at an exercise price equal to $1.74 per share.

Consulting Arrangements

During the nine months ended September 30, 2018, the Company issued 206,446 shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $1.3 million was recognized as stock-based compensation expense, $1.2 million in general and administrative expenses and $0.1 million in research and development expenses.

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2018 and changes during the period is presented below:

						Weighted Average
	Number of			Weighted Average		Remaining Contractual		Total Intrinsic
	Warrants			Exercise Price		Life (in years)		Value
Balance - January 1, 2018		6,520,000		$	6.11		3.16	$	1,739,000
Issued		-			-		-		-
Cashless exercised		(215,000	)		4.04		-		-
Exercised for cash		(1,497,000	)		6.79		-		-
Expired or cancelled		(156,000	)		4.00		-		-
Balance - September 30, 2018		4,652,000		$	6.06		2.50	$	17,583,000

Note 8: STOCK-BASED COMPENSATION

The following table sets forth stock-based compensation expenses recorded during the respective periods:

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2018		2017		2018		2017
Stock Compensation expenses:
Research and development	$	189,000	$	18,700	$	656,000	$	56,100
General and administrative		662,000		1,667,300		1,291,000		2,276,900
Total stock compensation expenses	$	851,000	$	1,686,000	$	1,947,000	$	2,333,000

At September 30, 2018, the total stock-based compensation cost related to unvested awards not yet recognized was $108,000. The expected weighted average period compensation costs to be recognized was 0.40 years. Future option grants will impact the compensation expense recognized.

Note 9: grant income

During the nine months ended September 30, 2018 and 2017, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” issued by the Financial Accounting Standards Board, the Company recorded the $0.2 million of grant income as revenue.

Note 10: SUBSEQUENT EVENT

The Merger

The accounting for the business combination accounting is not complete. The Company is in the process of concluding on the total fair value of consideration issued and the allocation of fair value of assets acquired and liabilities assumed and therefore such information has not been concluded in these financial statements.

Securities Purchase Agreements

On October 17, 2018, concurrent with the completion of the Merger, the Company issued to certain accredited investors in a private placement transaction (the “Financing”), an aggregate of 17,500,000 shares of its common stock, and warrants to purchase 13,437,500 shares of common stock at an exercise price of $5.00 per share with a five-year term, for gross proceeds of $70 million pursuant to the terms of the Securities Purchase Agreements, dated June 8, 2018, by and among the Company and certain accredited investors (the “Securities Purchase Agreements”). Upon consummation of the Financing, and as a condition to the Securities Purchase Agreements, the Company is, among other things, obligated to file a resale registration statement with the SEC within 15 days following completion of the Financing.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve risks and uncertainties. All statements other than statements relating to historical matters including statements to the effect that we “believe”, “expect”, “anticipate”, “plan”, “target”, “intend” and similar expressions should be considered forward-looking statements. Our actual results could differ materially from those discussed in the forward-looking statements as a result of a number of important factors, including factors discussed in this section and elsewhere in this quarterly report on Form 10-Q, and the risks discussed in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis, judgment, belief or expectation only as the date hereof. We assume no obligation to update these forward-looking statements to reflect events or circumstance that arise after the date hereof.

As used in this quarterly report: (i) the terms “we”, “us”, “our”, “Marker” and the “Company” mean Marker Therapeutics, Inc. and its wholly owned subsidiaries, Marker Cell Therapy, Inc. and GeneMax Pharmaceuticals Inc. which wholly owns GeneMax Pharmaceuticals Canada Inc., unless the context otherwise requires; (ii) “SEC” refers to the Securities and Exchange Commission; (iii) “Securities Act” refers to the Securities Act of 1933, as amended; (iv) “Exchange Act” refers to the Securities Exchange Act of 1934, as amended; and (v) all dollar amounts refer to United States dollars unless otherwise indicated.

The following should be read in conjunction with our unaudited condensed consolidated interim financial statements and related notes for the three and nine months ended September 30, 2018 included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2017 filed on March 23, 2018.

Company Overview

We are a clinical-stage immuno-oncology company specializing in the development and commercialization of innovative cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications and novel peptide-based vaccines for the treatment of breast and ovarian cancers.

Our cell-based immunotherapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells recognizes multiple tumor targets to produce broad spectrum anti-tumor activity. Because we do not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with potentially meaningful clinical benefit. As a result, we believe our portfolio of T cell therapies has a potentially compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. In addition, our legacy Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and its HER2/neu program (TPIV100/110) are in five Phase II clinical trials. In parallel, we have been working on a proprietary nucleic acid-based antigen expression technology named PolyStart™ to improve the ability of the immune system to recognize and destroy diseased cells.

Immuno-oncology, which utilizes a patient’s own immune system to combat cancer, is one of the most actively pursued areas of research by biotechnology and pharmaceutical companies today. Interest and excitement about immunotherapy is driven by compelling efficacy data in cancers with historically bleak outcomes, and the potential to achieve a cure or functional cure for some patients. Harnessing the power of the immune system is an important component of fighting cancerous cells in the body. Our MultiTAA T cell therapy platform identifies and selects for effectively all T cells that are specific for any peptide from the antigens that our targets (e.g., WT1, MAGE-A4, PRAME, Survivin, NY-ESO-1, and SSX2). Our in-vitro manufacturing process promotes proliferation of very rare cancer-killing T cells to augment their anti-tumor properties and provide benefit to patients following their infusion. By using the multi-antigen targeted approach, our proprietary technology can kill heterogeneous tumor cell populations more effectively than single-antigen targeted approaches, thereby reducing the likelihood of tumor escape and potentially increasing the durability of a patient’s response to therapy.

Recent Developments

Merger Agreement

The issuance of the shares of Company common stock to the former stockholders of Marker Cell in connection with the Merger and related transactions was approved by the Company’s stockholders at the 2018 annual meeting of stockholders (the “2018 Annual Meeting”) held on October 16, 2018.

In connection with the Merger, the Company filed an amendment to its articles of incorporation in Nevada to increase the authorized shares of common stock from 41,666,667 shares to 150,000,000 shares and to change the Company’s name to Marker Therapeutics, Inc. (“Certificate of Amendment”). The Company then reincorporated from a Nevada corporation to a Delaware corporation and filed its certificate of incorporation in Delaware. Finally, a certificate of merger was filed in Delaware to merge Marker Cell Therapy, Inc. (f/k/a Marker Therapeutics, Inc.) with and into Merger Sub, with Marker Cell Therapy, Inc. being the surviving corporation and wholly owned subsidiary of the Company. The name change, reincorporation and Merger were all effective as of October 17, 2018. Beginning as of the market open on October 18, 2018, shares of the Company’s common stock commenced trading on The Nasdaq Capital Market under its new ticker symbol “MRKR”.

Securities Purchase Agreements

On October 17, 2018, concurrent with the completion of the Merger, the Company issued to certain accredited investors in a private placement transaction (the “Financing”), an aggregate of 17,500,000 shares of its common stock, and warrants to purchase 13,437,500 shares of common stock at an exercise price of $5.00 per share with a five-year term, for aggregate proceeds of $70 million pursuant to the terms of the Securities Purchase Agreements, dated June 8, 2018, by and among the Company and certain accredited investors (the “Securities Purchase Agreements”). Upon consummation of the Financing, and as a condition to the Securities Purchase Agreements, the Company is, among other things, obligated to file a resale registration statement with the SEC within 15 days following completion of the Financing.

After taking into account the issuance of shares in the Financing described above, immediately following the effective time of the Merger, the pro forma ownership of the issued and outstanding shares of Company common stock on a fully diluted basis (assuming all issued and outstanding warrants and options are exercised) will be approximately as follows: Marker Cell’s former stockholders 27.5%, Company stockholders prior to the Merger 27.5%, and the private placement stockholders 45%. Following the completion of the Merger and the Financing, there were 45,328,510 issued and outstanding shares of the Company’s common stock.

Products and Technology in Development

The following chart sets forth our products and technologies under development.

Our MULTI TAA T Cell Products

We are advancing two legacy Marker Cell products through clinical development:

Mixed Antigen Peptide Pool (“MAPP”) T cells, which are currently used for patients with lymphoma, multiple myeloma and selected solid tumors, is an autologous product that targets the NY-ESO-1, PRAME, MAGE-A4, Survivin and SSX2 antigens, and

Leukemia Antigen Peptide Pool (“LAPP”) T cells, which are used for patients with AML, is an allogeneic product targeting the WT1, NY-ESO-1, PRAME, and Survivin antigens using the blood of the stem cell donor as a source of the cells used for therapy.

While the blood source and the antigens for stimulation differ between the LAPP and the MAPP products, the manufacturing process for each product is otherwise identical.

Even if the single-antigen specific therapy can eliminate all the tumor cells expressing the targeted antigen, the residual tumor cells that do not express that antigen may survive and expand. In addition, tumor cells may also downregulate or mutate the targeted antigen, thus becoming invisible to the T cell therapy. Both phenomena create a transformed tumor that is impervious to that therapy. This process is referred to as antigen-negative tumor immune escape.

Our solution to the problem of tumor heterogeneity was to develop T cell products that simultaneously attack multiple tumor-expressed antigens and thereby enable more complete initial tumor targeting, thus minimizing the subsequent opportunity for the cancer to engage escape mechanisms. Of note, data suggest this strategy may be responsible for recruitment and activation of unique cancer-killing cells from the patient’s own immune repertoire to participate in cancer eradication, further minimizing the possibility for tumor cell escape.

Our proprietary MultiTAA T cell platform may have meaningful advantages over current CAR-T and TCR cell therapy approaches. Compared to current gene-modified T cell therapies, our programs are characterized by the following:

• Demonstrated clinical benefit, without the need for lymphodepletion before infusion: In our Phase I lymphoma study, we saw complete responses (“CRs”) in 50 – 60% of its evaluable patients. We believe it is significant that no patient with a CR has subsequently relapsed with disease, whereas typically 30% or more of patients with CR in reported CAR-T studies relapse within one year. In patient results to date, observed therapeutic responses appear to be highly durable, with some patients being relapse-free beyond two years.

• Non-gene-modified: Unlike CAR-T and TCR approaches, our therapy requires no genetic modification of T cells, a costly and complex process that significantly complicates the manufacturing of a patient product. We believes our therapy can be manufactured at a fraction of the cost of a gene-modified T cell product, with substantially reduced complexity of manufacturing.

• Low incidence rate of adverse events: In approximately 60 patients treated to date, we have seen only one grade III adverse reaction possibly related to our therapy. This appears to compare favorably with published CD19 CAR-T studies, wherein up to 95% of patients had associated grade III or higher adverse events during treatment. We believe that it is notable that there have been no cases of cytokine-release syndrome (“CRS”), or related serious adverse events (“SAEs”) in patients treated with its therapy to date.

• Capable of addressing a broad repertoire of cancer cells: While CAR-T and TCR therapies generally target a single epitope, our manufacturing process selects for T cells that are specific for multiple peptides derived from several targeted antigens. Deep gene sequencing of our products shows that a typical patient dose usually consists of approximately 4,000 unique T cell clonotypes targeting up to five different tumor-associated antigens. In layman’s terms, the five antigen targets can be recognized by a very wide range of T cells, facilitating robust killing of targeted cancer cells.

• Appears to drive endogenous immune responses: We see evidence of “epitope spreading” in its patients, meaning that our therapy is potentially inducing an enhanced response by the patient’s own T cells (specific for an expanded set of tumor-associated antigens beyond those targeted by our infused product). Our correlative analyses show expansion of endogenous T cells, other than those present in our product, in the months following the infusion of our product. This phenomenon, also known as “antigen spreading,” is potentially important in generating a durable response for a patient, because it enables the killing of tumors that do not express any of the antigens initially targeted by our product.

Our Folate Products

Folate Receptor alpha (“FRa”) is overexpressed in over 80% of breast cancers and in addition, over 90% of ovarian cancers, for which the only treatment options are surgery, radiation therapy and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic strategy. Time to recurrence is relatively short for ovarian cancer and survival prognosis is extremely poor after recurrence. In the United States alone, there are approximately 30,000 ovarian cancer patients and 40,000 triple-negative breast cancer patients newly diagnosed every year. The FRa vaccine (now called TPIV200) intended to treat these conditions is composed of a mixture of five FRa immunogenic peptides adjuvanted with low-dose granulocyte-macrophage colony-stimulating factor GM-CSF.

GMP Manufacturing Scale Up of TPIV200 and Production to Supply Additional Phase II Clinical Trials

We have developed a commercial-quality lyophilized formulation of the TPIV200 peptides in a single vial for reconstitution and injection. Multi-gram peptide production scale-up has been successfully concluded, as well as GMP manufacturing of a second clinical lot of the TPIV200 peptides. The supply will be used in the company’s ongoing Phase II study in platinum-sensitive ovarian cancer, as well as the 280-patient Phase II study sponsored by the Mayo Clinic and funded by the U.S. Department of Defense (DoD) for treating triple-negative breast cancer. We also made various improvements to the vaccine manufacturing process, resulting in what we believe to be a superior formulation of the vaccine that is more amenable to large-scale manufacturing and commercialization. Thus, Good Manufacturing Practice (“GMP”) manufacturing development for the Phase II trials has been completed.

Phase I Human Clinical Trial – Folate Alpha Breast and Ovarian Cancers – Mayo Clinic

On July 27, 2015, we exercised our option agreement with Mayo Foundation with the signing of a worldwide exclusive license agreement to commercialize the proprietary FRa vaccine technology for all cancer indications. As part of this agreement, the IND for the Folate Receptor alpha Phase I trial was transferred from Mayo Foundation to the Company for Phase II clinical trials as our lead product.

The results from the initial 21-patient Phase I clinical trial for the FRa vaccine have now been reported. Twenty-one patients with breast or ovarian cancer, who had undergone standard surgery and adjuvant treatment, were treated with one cycle of cyclophosphamide. Following this, patients were vaccinated intradermally with TPIV200 on day one of a 28-day cycle for a maximum of six vaccination cycles. On March 15, 2018, we announced the publication of the clinical data from this trial. The results show that over 90% developed robust and durable antigen-specific immune responses against FRa without regard for HLA type, which aligns with the intended mechanism of action of the vaccine. TPIV200 vaccine was safe and well-tolerated; 20 out of 21 evaluable patients showed positive immune responses, providing a strong rationale for progressing to Phase II trials. Further, the data showed that 16 out of 16 patients in the observation stage showed persistent immune responses (Source: published online 15Mar2018; DOI: 10.1158/1078-0432.CCR-17-2499).

Phase II Development of TPIV200 for Triple-negative Breast Cancer

Triple-negative breast cancer (TNBC) is one of the most difficult cancers to treat and represents a clear unmet medical need. On September 15, 2015, we announced that our collaborators at the Mayo Foundation had been awarded a grant of $13.3 million from the DoD. This grant led by Dr. Keith Knutson of the Mayo Clinic in Jacksonville, Florida covers the costs for a 280-patient Phase II clinical trial of the FRa vaccine in patients with TNBC. We are working closely with Mayo Foundation on this clinical trial by providing clinical and manufacturing expertise, as well as providing GMP vaccine formulations under contract. This Phase II study of TPIV200 in the treatment of triple-negative breast cancer began enrolling patients in late 2017 and enrollment continues. Details regarding this trial can be found at www.clinicaltrials.gov under identifier numbers NCT03012100 and RU011501I.

On June 21, 2016, we announced the initiation of a randomized four-arm Phase II trial of TNBC that is sponsored and conducted by the Company (FRV-002), enrolling women with stage I-III disease who have completed initial surgery and chemo/radiation therapy. This open-label, 80-patient clinical trial is designed to evaluate dosing regimens, pre-treatment, efficacy, and immune responses. The study is evaluating two doses of TPIV200 (a high dose and a low dose), each of which will be tested both with and without immune priming with cyclophosphamide prior to vaccination. Key data from the trial is expected to be included in a future Biologics License Application submission to the FDA for marketing clearance. We completed enrollment in late 2017 and are now treating and following the patients. An independent Data Safety Monitoring Board (DSMB) reviews the safety in this ongoing Phase II study; no safety issues have been identified to date. Details regarding this trial can be found at www.clinicaltrials.gov under the identifier number NCT02593227.

Phase II Development of TPIV200 for Ovarian Cancer

On December 9, 2015, we announced that we received Orphan Drug Designation from the U.S. Food & Drug Administration’s Office of Orphan Products Development (“OOPD”) for our cancer vaccine TPIV200 in the treatment of ovarian cancer. The TPIV200 ovarian cancer clinical program will now receive benefits including tax credits on clinical research and seven-year market exclusivity upon receiving marketing approval. TPIV200 is a multi-epitope peptide vaccine that targets Folate Receptor alpha which is overexpressed in multiple cancers including over 90% of ovarian cancer cells. On February 3, 2016, we announced that the U.S. FDA designated the investigation of the multiple-epitope TPIV200 vaccine for maintenance therapy in subjects with platinum-sensitive advanced ovarian cancer who achieved stable disease or partial response following completion of standard-of-care chemotherapy, as a Fast Track Development Program.

On April 21, 2016, we announced our participation in an ovarian cancer study sponsored by Memorial Sloan Kettering Cancer Center (MSKCC) in New York City in collaboration with AstraZeneca Pharmaceuticals in ovarian cancer patients who are not responsive to platinum, a commonly used chemotherapy for ovarian cancer. This study, an open-label Phase II study of TPIV200 in 40 patients is designed to look at the effects of combination therapy with AstraZeneca’s checkpoint inhibitor durvalumab (anti-PD-L1). Because they are unresponsive to platinum, these patients have no real remaining options. Interim results from the first 27 patients were presented at the AACR-Rivkin Symposium in September 2018; safety of the combination was established in these heavily-pretreated patients and a subset of patients exhibited durable disease stabilization. ORR and PFS with combination treatment was not superior from the expected efficacy of single-agent PD-1/PD-L1 blockade. However, post-immunotherapy follow-up was suggestive of improved clinical benefit from standard therapies, as the majority of patients post-progression went on to receive subsequent standard therapy with durable clinical benefit, creating a rationale for exploration of these agents in combination with chemotherapy. Although we have no business relationship with AstraZeneca, we are paying for one-half of the costs of the clinical study, in addition to providing our TPIV200 for the study. Details regarding this trial can be found at www.clinicaltrials.gov under identifier numbers NCT02764333.

On January 10, 2017, we announced the initiation of a Company-sponsored Phase II study in platinum-sensitive ovarian cancer patients (FRV-004). This multi-center, double-blind efficacy study is designed to evaluate TPIV200 compared to GM-CSF alone in a randomized, placebo-controlled fashion during the first maintenance period after primary surgery and chemotherapy. Patients at this stage of their treatment have the highest potential for an immunotherapeutic effect and no other approved treatment options. We have opened multiple clinical sites and enrollment of the 120 patients has proceeded ahead of schedule. Safety is reviewed by an independent DSMB quarterly and an interim efficacy analysis is planned in 2019, once 50 patients have progressed. Details regarding this trial can be found at www.clinicaltrials.gov under the identifier number NCT02978222.

TPIV 100/110 – HER2/neu peptides with GM-CSF

Human epidermal growth factor receptor 2 (HER2/neu) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Over-expressed HER2 is detected predominantly in malignancies of epithelial origin, such as breast, gastric, esophageal, colorectal, salivary gland, pancreatic, epithelial ovarian, endometrial, and bladder carcinomas, as well as gallbladder and extrahepatic cholangiocarcinomas. HER2 is over-expressed in approximately 25% of breast cancers and its expression is associated with unfavorable pathologic features and aggressive disease if not treated with targeted therapies, relative to other forms of breast cancer. While the outcome of patients with HER2 positive breast cancer has significantly improved in the past few decades with an advent of anti-HER2 therapies, a substantial number of resected patients still subsequently develop metastatic disease. The continued prevalence of these cancers represents a high unmet medical need, justifying the targeted development of immunotherapeutic strategies.

Phase I Human Clinical Trial – HER2/neu+ Breast Cancer – Mayo Clinic

A Phase I study using a vaccine containing four HER2/neu peptides adjuvanted with GM-CSF (now called TPIV100) was initiated in 2012 at the Mayo Clinic and the primary readout was completed in 2015. Final safety analysis on all the patients treated showed that the vaccine was safe in that context. In addition, 19 out of 20 evaluable patients showed robust T-cell immune responses to the antigens in the vaccine composition providing a solid case for advancement to Phase II. Data from the study was presented at the San Antonio Breast Cancer Symposium on December 10, 2015. An additional secondary endpoint incorporated into this Phase I Trial will be a two-year follow-on recording the time to disease recurrence in the participating breast cancer patients. Details regarding this trial can be found at www.clinicaltrials.gov under the identifier number NCT01632332.

Transition of the HER2/neu Vaccine

On June 7, 2016, we announced that the Company had exercised its option agreement with Mayo Clinic and signed a worldwide license agreement to the proprietary HER2/neu vaccine technology. The license gives the Company the right to develop and commercialize the technology in any cancer indication in which the Her2/neu antigen is overexpressed. As part of this agreement, the IND for the HER2/neu Phase I Trial was transferred from Mayo Foundation to the Company for Phase II clinical trials as TPIV100, our second product.

On March 14, 2017, we announced that our partners at the Mayo Clinic received a $3.8 million grant from the DoD to conduct a Phase Ib study of the HER2-targeted vaccine candidate in an early form of breast cancer called ductal carcinoma in situ (DCIS). This is the second Company vaccine to be tested in a fully-funded study sponsored by the Mayo Clinic. We are working closely with Mayo Foundation on this clinical trial by providing clinical and manufacturing expertise, as well as providing GMP vaccine formulations under contract. If the study is successful, our HER2/neu vaccine may eventually augment or even replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women. The study is expected to enroll 40 – 45 women with DCIS and begin to commence such enrollment during late 2018.

Phase II Development of the HER2/neu TPIV110 Vaccine

For subsequent clinical studies, we have added a Class I peptide, also licensed from the Mayo Clinic on April 16, 2012, to the four Class II peptides, producing TPIV 110 when the five peptides are mixed with GM-CSF. Management believes that the combination of Class I and Class II HER2/neu antigens, gives us the leading HER2/neu vaccine platform. We are amending the IND to incorporate the fifth peptide in subsequent studies to produce an even more robust vaccine activating both CD4+ (helper) and CD8+ (killer) T-cells. Discussions with the FDA have resulted in similar Phase II manufacturing process development that we conducted for TPIV200 that should allow us to file the amended IND for TPIV110 in late-2018.

On October 10, 2018, we announced that Mayo Clinic had been awarded a grant of $11 million from the DoD. This grant is intended to cover the costs of a large randomized, double-blind Phase 2 study of the Company’s HER2/neu-targeted breast cancer vaccine, TPIV110 compared to GM-CSF alone, in combination with trastuzumab (Herceptin®) and pertuzumab (Perjeta®), for treating up to 190 women with HER2/neu-positive breast cancer. We are working closely with Mayo Foundation on this clinical trial by providing clinical and manufacturing expertise, as well as providing GMP vaccine formulations under contract. The study will ask whether the administration of vaccine during trastuzumab and pertuzumab maintenance therapy in patients with residual disease post-neoadjuvant chemotherapy blocks disease recurrence and the development of metastatic breast cancer. By prevention of recurrence and metastasis, the expectation is that mortality associated with breast cancer will be decreased. Aside from the immunization component of the approach, another unique aspect is study of the role of the immune response, induced by monoclonal antibody therapy, in the neoadjuvant setting by engaging another 190 patients that demonstrated complete pathologic response to therapy but who do not get vaccine, potentially enabling a better understanding of mechanisms of immune escape.

Products and Technology – Pre-clinical

Polystart

In addition to the clinical developments, our peptide vaccine technology can be coupled with our PolyStart™ nucleic acid-based technology, which is designed to make vaccines significantly more effective by producing four times the required peptides for the immune systems to recognize and act on.

On February 7, 2017, we announced that we received a Notice of Allowance from the U.S. Patent and Trademark Office of our patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof,” which represents our first patent on our Polystart program.

On March 22, 2018, a Notice of Allowance was received that expanded the claims beyond FRA or Her2/neu peptide epitopes to broadly include any polypeptide portion comprising any poly-antigen arrays (PAAs) (i.e., for any tumor antigen or any infectious pathogen). We anticipate additional patent filings in connection with our research and development in this area. We plan to develop Polystart as both a stand-alone therapy and as a ‘boost strategy’ to be used synergistically with our peptide-based vaccines for breast and ovarian cancers.

Results of Operations

In this discussion of the Company’s results of operations and financial condition, amounts, other than per-share amounts, have been rounded to the nearest thousand dollars.

Three Months Ended September 30, 2018 Compared to Three Months Ended September 30, 2017

We recorded a net loss of $4.4 million or ($0.32) basic and diluted per share during the three months ended September 30, 2018 compared to a net loss of $4.0 million or ($0.39) basic and diluted per share during the three months ended September 30, 2017. The change in net loss period over period was due to the following changes:

Revenue

Grant income

During the three months ended September 30, 2017, we received $183,000 of a grant awarded to Mayo Foundation from the US Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated us for clinical supplies manufactured by us and provided for the clinical study.

Operating Expenses

Operating expenses incurred during the three months ended September 30, 2018 were $4.4 million compared to $4.2 million in the prior period. Significant changes in operating expenses are outlined as follows:

Research and development costs during the three months ended September 30, 2018 were $1.9 million compared to $1.6 million during the prior year period. The three months ended September 30, 2018 had increased expenses from the prior period relating to our clinical trials.

General and administrative expenses were $2.6 million during the three months ended September 30, 2018 as compared to $2.5 million during the prior year period. This slight increase was due to increased expenses relating to:

$0.2 million of headcount-related expenses,

$0.5 million of legal and other expenses relating to the announced merger agreement, and

$0.2 million of other miscellaneous general and administrative expenses.

For the three-month period ended September 30, 2017, we recorded $0.8 million of stock-based compensation expenses relating to stock grants pursuant to Peter Hoang’s and Glynn Wilson’s employment agreements. These savings partially offset the increased expenses identified above.

Other Expense

Change in fair value of warrant liabilities

The change in fair value of warrant liabilities for the three months ended September 30, 2018 was ($40,000) as compared to ($4,000) for the three months ended September 30, 2017. This decrease by $40,000 for the three months ended September 30, 2018 is reflected by a corresponding other income in the condensed consolidated statement of operations.

Nine Months Ended September 30, 2018 Compared to Nine Months Ended September 30, 2017

We recorded a net loss of $12.4 million or ($1.03) basic and diluted per share during the nine months ended September 30, 2018 compared to a net loss of $8.3 million or ($0.91) basic and diluted per share during the nine months ended September 30, 2017. The change in net loss period over period was due to the following:

Revenue

Grant income

During the nine months ended September 30, 2018, we received $206,000 of a grant awarded to Mayo Foundation from the US Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated us for clinical supplies manufactured by us and provided for the clinical study. During the nine months ended September 30, 2017, we received $183,000 of grant income.

Operating Expenses

Operating expenses incurred during the nine months ended September 30, 2018 were $12.5 million compared to $9.0 million in the prior period. Significant changes in operating expenses are outlined as follows:

Research and development costs during the nine months ended September 30, 2018 were $5.3 million compared to $3.8 million during the prior year period. The nine months ended September 30, 2018 had increased expenses from the prior period relating to our clinical trials.

General and administrative expenses increased to $7.2 million during the nine months ended September 30, 2018 from $5.2 million during the prior year period. This was due to increased expenses relating to:

$0.2 million of stock-based compensation expenses for employees and outside consultants,

$0.3 million of headcount-related expenses,

$2.2 million of expenses relating to the announced merger agreement, and

$0.1 million of investor relations expenses.

For the nine-month period ended September 30, 2017, we recorded $0.8 million of stock-based compensation expenses relating to stock grants pursuant to Peter Hoang’s and Glynn Wilson’s employment agreements. These savings partially offset the increased expenses identified above.

Other Expense

Change in fair value of warrant liabilities

The change in fair value of warrant liabilities for the nine months ended September 30, 2018 was $98,000 as compared to ($9,000) for the nine months ended September 30, 2017. This increase by $98,000 for the nine months ended September 30, 2018 is reflected by a corresponding other expense in the condensed consolidated statement of operations.

Debt extinguishment gain

In 2003 we entered into a license agreement with a foreign based third-party for certain adenovirus technology. The license agreement was amended several times between inception and 2008 at which time it was amended and restated and had a fixed three-year term expiring in 2011. During such time, we did not pursue the technology and have not undertaken further work in the area covered by the technology license. Neither we nor the third-party took further actions under or pursuant to the license agreement. We carried a historical accrual of approximately $0.5 million under the amended license agreement related to certain obligations provided for in the license agreement. The license agreement was governed by the laws of a foreign jurisdiction. We sought and obtained legal advice related to such accrued obligations under the expired license agreement. We relied upon a judicial conclusion, as opined upon by outside legal counsel in the applicable foreign jurisdiction, that a court in such foreign jurisdiction would grant relief releasing us from liability under the license agreement, and in accordance with Accounting Standards Codification 405 “Extinguishment of Liabilities”, we recorded a debt extinguishment gain of $0.5 million and reduced the liability amount owed to $0 during the nine months ended September 30, 2017.

Liquidity and Capital Resources

We have not generated any revenues since inception other than revenue form grants we received. We have financed our operations primarily through public and private offerings of our stock and debt including warrants and the exercises thereof.

The following table sets forth our cash and working capital as of September 30, 2018 and December 31, 2017:

	September 30,		December 31,
	2018		2017
Cash	$	4,294,000	$	5,129,000
Working Capital	$	690,000	$	3,658,000

Cash Flows

The following table summarizes our cash flows for the nine months ended September 30, 2018 and 2017:

	Nine Months Ended
	September 30,
	2018			2017
Net Cash provided by (used in):
Operating activities	$	(8,317,000	)	$	(5,961,000	)
Financing activities		7,482,000			5,717,000
Net decrease in cash	$	(835,000	)	$	(244,000	)

Financings

Our financing activities during the nine months ended September 30, 2018 were as follows:

Common Stock Purchase Agreement

Exercise and Repricing of Warrants Held by Existing Institutional Investors

The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000.

Exercise of Stock Warrants

Exercise of Stock Options

In January 2018, a former officer exercised 10,416 shares of common stock pursuant to stock options providing proceeds of $18,000.

Other Financings

Securities Purchase Agreements

Future Capital Requirements

As of September 30, 2018, we had working capital of $0.7 million, compared to working capital of $3.7 million as of December 31, 2017.

We expect our expenses to steadily increase as we move forward with the efforts in carrying out our clinical development plans, including those to be initiated from our new subsidiary Marker Cell. Three of our clinical studies are expected to be funded by a total of approximately $28 million of grants made by the DOD to the Mayo Clinic. We believe our existing cash, inclusive of the funds received from our recently closed private placement financing will fund our operations into mid-2020. We will require additional capital in the future to continue conducting research and development, to fund Phase II clinical trials of our licensed, patented technologies, to fund non-clinical testing and to possibly begin cultivating collaborative relationships for the Phase II and future Phase III clinical testing. Our plans could include seeking both equity and debt financing, alliances or other partnership agreements with entities interested in our technologies, or other business transactions that could generate sufficient resources to ensure continuation of our operations and research and development programs.

We expect to continue to seek additional funding for our operations and future capital requirements. Any such required additional capital may not be available on reasonable terms, if at all. If we were unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned clinical testing and research and development activities, which could harm our business. The sale of additional equity or debt securities may result in additional dilution to our shareholders. If we raise additional funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those holders of our common stock and could contain covenants that could restrict our operations. We also will require additional capital beyond our currently forecasted amounts.

Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates, we are unable to estimate the exact amounts of our future working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

the number and characteristics of the product candidates we pursue;

the scope, progress, results and costs of researching and developing our product candidates;

strategic transactions we may undertake;

the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;

our ability to maintain current research and development licensing agreements and to establish new strategic partnerships and collaborations, licensing or other arrangements and the financial terms of such agreements;

our ability to achieve our milestones under our licensing arrangements and the payment obligations we may have under such agreements;

the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and

the timing, receipt and amount of sales of, or royalties on, our future products, if any.

We have based our estimates on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate.

Various conditions outside of our control may detract from our ability to raise additional capital needed to execute our plan of operations, including overall market conditions in the international and local economies. Any of these factors could have a material impact upon our ability to raise financing and, as a result, upon our short-term or long-term liquidity.

Critical Accounting Policies

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results could differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2017.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes of financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4.

Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act.

It should be noted that any system of controls is based in part upon certain assumptions designed to obtain reasonable (and not absolute) assurance as to its effectiveness, and there can be no assurance that any design will succeed in achieving its stated goals.

(b)

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the nine months ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

Management is not aware of any material legal proceedings and there are no pending material proceedings that would affect the property of the Company. Management is not aware of any legal proceedings contemplated by any government authority or any other party involving the Company.

As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceeding.

Item 1A.

Risk Factors

In addition to the risk factors set forth in Part I — Item 1A — “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (the “10-K”) and Part II — Item 1A — “Risk Factors” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2018 and June 30, 2018 (the “10-Q”), investors should consider the risk factors arising from our “merger of equals” business combination (the “merger”) as well as the other risk factors set forth in the definitive proxy statement we filed with the SEC on September 14, 2018 and the Form 8-K filed on October 30, 2018.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

(a)

We issued the following unrestricted securities during the period covered by this report to the named individual pursuant to exemptions under the Securities Act of 1933 including Section 4(2):

On August 31, 2018, we issued 50,000 shares of common stock to Caro Partners, LLC pursuant to a vendor agreement.

On September 4, 2018, we issued 5,800 shares of common stock to Corporate Profile pursuant to a vendor agreement.

On September 12, 2018, we issued 15,000 shares of common stock to Omnicor Media, LLC pursuant to a vendor agreement.

On September 21, 2018, we issued 2,821 shares of common stock to Richard Kenney, pursuant to a consulting services agreement.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosure

Not applicable.

Item 5.

Other Information

Not applicable.

Item 6.

Exhibits

The following exhibits are included with this Quarterly Report on Form 10-Q:

Incorporated by Reference

Exhibit
number

Exhibit description

Form

File no.

Exhibit

Filing

date

Filed

herewith

2.1

Agreement and Plan of Merger and Reorganization, dated as of May 15, 2018, by and among TapImmune Inc., Timberwolf Merger Sub, Inc. and Marker Therapeutics, Inc.

Certificate of Incorporation

Bylaws of Marker Therapeutics, Inc.

4.1	2014 Omnibus Stock Ownership Plan, as amended through August 29, 2017 (incorporated by reference as Exhibit 4.1 to the Form S-8 Registration Statement (No. 333-223900) filed on March 3, 2018	8-K	001-37939	4.3	10/17/18

4.2	Amendment to the 2014 Omnibus Stock Ownership Plan, as amended through August 29, 2017.	8-K	001-37939	4.4	10/17/18

4.3	Form of Private Placement Warrant	8-K	001-37939	4.1	6/8/18

4.4	Form of Private Placement Warrant	8-K	001-37939	4.2	6/8/18

4.5	Form of Merger Warrant	8-K	001-37939	2.1	5/15/18

10.1	Form of Securities Purchase Agreement	8-K	001-37939	10.1	6/8/18

31.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.					X

31.2	Certification of Chief Financial Officer and Chief Accounting Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.					X

32.1	Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1933, as amended.					X

32.2	Certification of Chief Financial Officer and Chief Principal Accounting Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.					X

Exhibit 101

101.INS - XBRL Instance Document

101.SCH - XBRL Taxonomy Extension Schema Document

101.CAL - XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF - XBRL Taxonomy Extension Definition Linkbase Document

101.LAB - XBRL Taxonomy Extension Label Linkbase Document

101.PRE - XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 13, 2018

MARKER THERAPEUTICS, INC.

	/s/ Peter L. Hoang
	Peter L. Hoang President and Chief Executive Officer and Principal Executive Officer

	/s/ Michael J. Loiacono
	Michael J. Loiacono Chief Financial Officer and Principal Accounting Officer

EX-31.1 2 tv506096_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Peter L. Hoang, certify that:

(1)

I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2018 of Marker Therapeutics, Inc.;

(2)

Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

(4)

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this Report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2018

/s/ Peter L. Hoang
By:	Peter L. Hoang
Title:	Chief Executive Officer

EX-31.2 3 tv506096_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Michael J. Loiacono, certify that:

(1)

I have reviewed this Report on Form 10-Q for the quarterly period ended September 30, 2018 of Marker Therapeutics, Inc.;

(2)

(3)

(4)

(a)

(b)

(c)

(d)

(5)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2018

/s/ Michael J. Loiacono
By:	Michael J. Loiacono
Title:	Chief Financial Officer and Chief Accounting Officer

EX-32.1 4 tv506096_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Peter L. Hoang, the Chief Executive Officer of Marker Therapeutics, Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of Marker Therapeutics, Inc., for the quarterly period ended September 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Marker Therapeutics, Inc.

Date: November 13, 2018

	/s/ Peter L. Hoang
	Peter L. Hoang
	Chief Executive Officer

EX-32.2 5 tv506096_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF PRINCIPAL ACCOUNTING OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Michael J. Loiacono, the Chief Financial Officer and Chief Accounting Officer of Marker Therapeutics, Inc. (the “Company”) hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Report on Form 10-Q of Marker Therapeutics, Inc., for the quarterly period ended September 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Marker Therapeutics, Inc.

Date: November 13, 2018

	/s/ Michael J. Loiacono
	Michael J. Loiacono
	Chief Financial Officer and Chief Accounting Officer

GRAPHIC 6 tv506096_img1.jpg GRAPHIC begin 644 tv506096_img1.jpg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tv506096_img2.jpg GRAPHIC begin 644 tv506096_img2.jpg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

XML 15 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) Sep. 30, 2018 Dec. 31, 2017 Current assets: Cash $ 4,294,271 $ 5,129,289 Prepaid expenses and deposits 96,967 51,150 Total current assets 4,391,238 5,180,439 Total assets 4,391,238 5,180,439 Current liabilities: Accounts payable and accrued liabilities 3,588,771 1,508,312 Warrant liability 107,000 9,000 Promissory note 5,000 5,000 Total current liabilities 3,700,771 1,522,312 Total liabilities 3,700,771 1,522,312 COMMITMENTS AND CONTINGENCIES Stockholders' equity: Common stock, $0.001 par value, 41.7 million shares authorized, 13.8 million and 10.6 million shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 13,845 10,616 Additional paid-in capital 171,221,851 161,067,538 Accumulated deficit (170,545,229) (157,420,027) Total stockholders' equity 690,467 3,658,127 Total liabilities and stockholders' equity 4,391,238 5,180,439 Series A Preferred Stock [Member] Stockholders' equity: Preferred Stock, Value 0 0 Series B Preferred Stock [Member] Stockholders' equity: Preferred Stock, Value $ 0 $ 0 X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 + Details Name: us-gaap_DerivativeLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_NotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316 + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2018 Dec. 31, 2017 Preferred stock par value $ 0.001 $ 0.001 Preferred stock shares authorized/designated 5,000,000 5,000,000 Common stock shares par value $ 0.001 $ 0.001 Common stock shares authorized 41,700,000 41,700,000 Common stock shares issued 13,800,000 10,600,000 Common stock shares outstanding 13,800,000 10,600,000 Series A Preferred Stock [Member] Preferred stock par value $ 0.001 $ 0.001 Preferred stock shares authorized/designated 1,250,000 1,250,000 Preferred stock issued 0 0 Preferred stock outstanding 0 0 Series B Preferred Stock [Member] Preferred stock par value $ 0.001 $ 0.001 Preferred stock shares authorized/designated 1,500,000 1,500,000 Preferred stock issued 0 0 Preferred stock outstanding 0 0 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Sep. 30, 2018 Sep. 30, 2017 Revenues: Total revenues $ 0 $ 183,064 $ 205,994 $ 183,064 Operating expenses: Research and development 1,877,260 1,623,302 5,303,647 3,815,119 General and administrative 2,551,146 2,549,272 7,202,036 5,167,582 Total operating expenses 4,428,406 4,172,574 12,505,683 8,982,701 Loss from operations (4,428,406) (3,989,510) (12,299,689) (8,799,637) Other income (expense): Change in fair value of warrant liabilities 40,000 4,000 (98,000) 8,500 Debt extinguishment gain 0 0 0 492,365 Net loss $ (4,388,406) $ (3,985,510) $ (12,397,689) $ (8,298,772) Net loss per share, Basic and Diluted $ (0.32) $ (0.39) $ (1.03) $ (0.91) Weighted average number of common shares outstanding 13,733,406 10,219,138 12,082,176 9,081,678 Grant [Member] Revenues: Total revenues $ 0 $ 183,064 $ 205,994 $ 183,064 X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959 + Details Name: us-gaap_DerivativeGainLossOnDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesNo definition available. + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). + ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 18 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1 CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2018 - USD ($) Total Common Stock [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Balance, Amount at Dec. 31, 2017 $ 3,658,127 $ 10,616 $ 161,067,538 $ (157,420,027) Balance, Share at Dec. 31, 2017 10,615,724 Issuance of common stock in private placement, Amount 3,120,000 $ 1,300 3,118,700 0 Issuance of common stock in private placement, Share 1,300,000 Stock options exercised for cash, Amount 18,125 $ 10 18,115 0 Stock options exercised for cash, Share 10,416 Stock warrants exercised for cash, Amount 4,344,171 $ 1,497 4,342,674 0 Stock warrants exercised for cash, Share 1,496,881 Stock warrants cashless exercised, Amount 0 $ 215 (215) 0 Stock warrants cashless exercised, Share 215,336 Stock-based compensation, Amount 1,947,733 $ 207 1,947,526 0 Stock-based compensation, Share 206,446 Fair value of repriced warrants as inducement 0 $ 0 727,513 (727,513) Net loss (12,397,689) 0 0 (12,397,689) Balance, Amount at Sep. 30, 2018 $ 690,467 $ 13,845 $ 171,221,851 $ (170,545,229) Balance, Share at Sep. 30, 2018 13,844,803 X - DefinitionExercise of warrants amount. + ReferencesNo definition available. + Details Name: mrkr_ExerciseOfWarrantsAmount Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise of warrants share. + ReferencesNo definition available. + Details Name: mrkr_ExerciseOfWarrantsShare Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPrivate placement amount. + ReferencesNo definition available. + Details Name: mrkr_PrivatePlacementAmount Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrivate placement share. + ReferencesNo definition available. + Details Name: mrkr_PrivatePlacementShare Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe value of warrant exercised of non cash transaction amount. + ReferencesNo definition available. + Details Name: mrkr_WarrantOfCashlessExercised Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe warrant exercised of non cash transaction shares issued. + ReferencesNo definition available. + Details Name: mrkr_WarrantOfCashlessExercisedSharesIssued Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 19 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Cash Flows from Operating Activities: Net loss $ (12,397,689) $ (8,298,772) Reconciliation of net loss to net cash used in operating activities: Changes in fair value of warrant liabilities 98,000 (8,500) Stock-based compensation 1,947,733 2,332,915 Debt extinguishment gain 0 (492,365) Changes in operating assets and liabilities: Prepaid expenses and deposits (45,817) (26,381) Accounts payable and accrued expenses 2,080,459 532,122 Net cash used in operating activities (8,317,314) (5,960,981) Cash Flows from Financing Activities: Proceeds from issuance of common stock and warrants in private placement, net of offering costs 3,120,000 5,408,343 Proceeds from exercise of stock warrants, net of offering costs 4,344,171 619,623 Proceeds from exercise of stock options 18,125 0 Repurchase of common stock to pay for employee withholding taxes 0 (310,493) Net cash provided by financing activities 7,482,296 5,717,473 Net decrease in cash (835,018) (243,508) Cash at beginning of period 5,129,289 7,851,243 Cash at end of period 4,294,271 7,607,735 Supplemental schedule of non-cash financing activities: Fair value of repriced warrants as inducement 727,513 622,042 Stock warrants cashless exercised $ 215 $ 0 X - DefinitionThe value of warrant exercised of non cash amount transaction. + ReferencesNo definition available. + Details Name: mrkr_NonCashExcerciseOfWarrantsAmount Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of repriced warrants as inducement which classified as non financing and investing activities. + ReferencesNo definition available. + Details Name: mrkr_NoncashOrPartNoncashTransactionFairValueOfRepricedWarrantsAsInducement Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity due to issue of common stock and warrants in a private placement. + ReferencesNo definition available. + Details Name: mrkr_ProceedsFromIssuanceOfCommonStockAndWarrantsInPrivatePlacement Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes. + ReferencesNo definition available. + Details Name: us-gaap_CashPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12355-112629 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=114001942&loc=d3e12317-112629 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInDerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of stock options granted under share-based compensation arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 20 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1 NATURE OF OPERATIONS 9 Months Ended Sep. 30, 2018 Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Note 1: Nature of Operations Marker Therapeutics, Inc., a Delaware corporation formerly known as TapImmune, Inc. (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of innovative cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, and novel peptide-based vaccines for the treatment of breast and ovarian cancers. The Company’s cell-based immunotherapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells recognizes multiple tumor targets to produce broad spectrum anti-tumor activity. Because the Company does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with potentially meaningful clinical benefit. As a result, the Company believes its portfolio of T cell therapies has a potentially compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. In addition, the Company’s legacy Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu program (TPIV100/110) are in a combined five Phase II clinical trials. In parallel, the Company has been working on a proprietary nucleic acid-based antigen expression technology named PolyStart™ to improve the ability of the immune system to recognize and destroy diseased cells. The Company was incorporated in Nevada in 1992 and reincorporated in Delaware in October 2018 in connection with the Marker Transaction. On October 17, 2018, the Company completed its previously announced business combination with Marker Cell Therapy, Inc., formerly known as Marker Therapeutics, Inc., a privately-held Delaware corporation (“Marker Cell”), in accordance with the terms of an Agreement and Plan of Merger and Reorganization dated as of May 15, 2018 (the “Merger Agreement”) by and among the Company, Timberwolf Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Marker. On October 17, 2018, pursuant to the Merger Agreement, Merger Sub was merged with and into Marker Cell (the “Merger”), with Marker Cell being the surviving corporation and becoming a wholly-owned subsidiary of the Company. In connection with the Merger, the Company changed its name to Marker Therapeutics, Inc. and Marker Cell changed its name to Marker Cell Therapy, Inc. At the effective time of the Merger, the former Marker Cell stockholders received (i) an aggregate of 13,914,255 shares of the Company’s common stock which equaled the number of shares of the Company’s common stock issued and outstanding immediately prior to the effective time of the Merger, and (ii) an aggregate of 5,046,003 warrants which equaled the number of the Company’s warrants and stock options issued and outstanding immediately prior to the effective time of the Merger. X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -URI http://asc.fasb.org/topic&trid=2134479 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1 BASIS OF PRESENTATION 9 Months Ended Sep. 30, 2018 Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION NOTE 2: Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results. The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2018 or for any future interim period. The condensed consolidated balance sheet at September 30, 2018 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2017, and notes thereto included in the Company’s annual report on Form 10-K filed on March 23, 2018 and the Company’s Form 8-K and Form 8-K/A filed on October 30, 2018 and October 26, 2018, respectively. X - DefinitionThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details Name: us-gaap_BasisOfAccounting Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1 LIQUIDITY AND FINANCIAL CONDITION 9 Months Ended Sep. 30, 2018 Text Block [Abstract] LIQUIDITY AND FINANCIAL CONDITION NOTE 3: LIQUIDITY AND FINANCIAL CONDITION As of September 30, 2018, the Company had cash of approximately $4.3 million. On October 17, 2018, concurrent with the completion of the merger with Marker Cell, the Company issued shares of its common stock to certain accredited investors in a private placement transaction for proceeds of $61.8 million , net of banker fees, pursuant to the terms of the Securities Purchase Agreement. The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities will span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. X - DefinitionLiquidity and financial condition text block. + ReferencesNo definition available. + Details Name: mrkr_LiquidityAndFinancialConditionTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1 SIGNIFICANT ACCOUNTING POLICIES 9 Months Ended Sep. 30, 2018 Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Note 4: SIGNIFICANT ACCOUNTING POLICIES There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 23, 2018. New Accounting Pronouncement s From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption. Recent Accounting Pronouncements Adopted in the Year Compensation-Stock Compensation In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company adopted ASU 2017-09 on January 1, 2018; the adoption of ASU 2017-09 did not have a material impact on its financial condition or results of operations, as the Company has not had any modifications to share-based payment awards. However, if the Company does have a modification to an award in the future, it will follow the guidance in ASU 2017-09. Revenue from Contracts with Customers In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue. Recent Accounting Pronouncements Not Yet Adopted Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB issued a two-part ASU, No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures. Improvements to Non-Employee Share-Based Payment Accounting In June 2018, the FASB issued ASU 2018-07 “Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new standard on its consolidated financial statements. Leases In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes ASC Topic 840, Leases. ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all the leases with terms greater than twelve months. Based on certain criteria, leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements” that allows entities to apply the provisions of the new standard at the effective date (e.g. January 1, 2019), as opposed to the earliest period presented under the modified retrospective transition approach (January 1, 2017) and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of Topic 842, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. The Company currently expects that most of its operating lease commitments will be subject to the new standard and recognized as operating lease liabilities and right-of-use assets upon its adoption of Topic 842, which will increase the total assets and total liabilities that the Company reports relative to such amounts prior to adoption. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements. SEC Disclosure Update and Simplification In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -URI http://asc.fasb.org/topic&trid=2122369 + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 24 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1 NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER 9 Months Ended Sep. 30, 2018 Noncontrolling Interest [Abstract] NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Note 5: NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similarly to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table sets forth the computation of net loss per share: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Numerator: Net loss $ (4,388,406 ) $ (3,985,510 ) $ (12,397,689 ) $ (8,298,772 ) Denominator: Weighted average common shares outstanding 13,733,406 10,219,138 12,082,176 9,081,678 Net loss per share data: Basic and Diluted $ (0.32 ) $ (0.39 ) $ (1.03 ) $ (0.91 ) The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented: Nine Months Ended September 30, 2018 2017 Common stock options 439,000 455,000 Common stock purchase warrants 4,625,000 6,517,500 Common stock warrants - liability treatment 27,000 3,500 Potentially dilutive securities 5,091,000 6,976,000 X - DefinitionThe entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -URI http://asc.fasb.org/topic&trid=2197479 + Details Name: us-gaap_MinorityInterestDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1 WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS 9 Months Ended Sep. 30, 2018 Derivatives and Fair Value [Abstract] WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS Note 6: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2018 and 2017 is as follows: September 30, September 30, 2018 2017 Stock price $ 9.05 $ 3.01 Exercise price $ 9.72 $ 1.20 Contractual term (years) 1.33 0.78 Volatility (annual) 86 % 63 % Risk-free rate 2 % 1 % Dividend yield (per share) 0 % 0 % The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations. Financial Liabilities Measured at Fair Value on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability: Fair value measured at September 30, 2018 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) September 30, 2018 Warrant liability $ - $ - $ 107,000 $ 107,000 Fair value measured at December 31, 2017 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) December 31, 2017 Warrant liability $ - $ - $ 9,000 $ 9,000 The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:  Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;  Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and  Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2018. The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2018: Warrant Liability Balance - December 31, 2017 $ 9,000 Change in fair value of warrant liability 98,000 Balance – September 30, 2018 $ 107,000 X - ReferencesNo definition available. + Details Name: mrkr_DerivativesAndFairValueAbstract Namespace Prefix: mrkr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivatives and fair value of assets and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -URI http://asc.fasb.org/topic&trid=2155941 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -URI http://asc.fasb.org/topic&trid=2229140 + Details Name: us-gaap_DerivativesAndFairValueTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 26 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCKHOLDERS' EQUITY 9 Months Ended Sep. 30, 2018 Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Note 7: STOCKHOLDERS’ EQUITY Common Stock Transactions Common Stock Purchase Agreement On May 14, 2018, the Company’s largest stockholder Eastern Capital Limited entered into a Common Stock Purchase Agreement with the Company pursuant to which it purchased 1,300,000 shares of common stock at a price per share of $2.40 providing gross proceeds to the Company of $3.12 million. Exercise and Repricing of Warrants Held by Existing Institutional Investors On May 14, 2018, certain institutional holders of outstanding warrants entered into Warrant Exercise Agreements with the Company that provide for an amendment to the exercise price of the warrants being exercised at $2.50 per share. Upon closing of the Warrant Exercise Agreements, such institutional holders immediately exercised warrants for 782,505 shares of common stock providing aggregate proceeds to the Company of approximately $2.0 million. The fair value relating to the modification of exercise prices on the repriced and exercised warrants was treated as deemed dividend on the statement of stockholders’ equity of $728,000. A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows: Weighted Average Inputs Before After Modification Modification Exercise price $ 9.93 $ 2.50 Contractual term (years) 2.37 2.37 Volatility (annual) 79 % 79 % Risk-free rate 1.5 % 1.5 % Dividend yield (per share) 0 % 0 % Exercise of Stock Warrants During the nine months ended September 30, 2018, certain outstanding warrants were exercised by warrant holders providing aggregate proceeds to the Company of approximately $2.4 million and resulted in the issuance of approximately 930,000 shares of common stock, which is net of 152,588 warrant shares cancelled due to use of cashless exercise provisions. 215,344 of the stock warrants exercised were exercised on a cashless basis. Exercise of Stock Options In January 2018, 10,416 shares of common stock were issued pursuant to stock option exercises at an exercise price equal to $1.74 per share. Consulting Arrangements During the nine months ended September 30, 2018, the Company issued 206,446 shares of common stock in connection with consulting agreements. The fair value of the common stock of approximately $1.3 million was recognized as stock-based compensation expense, $1.2 million in general and administrative expenses and $0.1 million in research and development expenses. Share Purchase Warrants A summary of the Company’s share purchase warrants as of September 30, 2018 and changes during the period is presented below: Weighted Average Number of Weighted Average Remaining Contractual Total Intrinsic Warrants Exercise Price Life (in years) Value Balance - January 1, 2018 6,520,000 $ 6.11 3.16 $ 1,739,000 Issued - - - - Cashless exercised (215,000 ) 4.04 - - Exercised for cash (1,497,000 ) 6.79 - - Expired or cancelled (156,000 ) 4.00 - - Balance - September 30, 2018 4,652,000 $ 6.06 2.50 $ 17,583,000 X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 27 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCK-BASED COMPENSATION 9 Months Ended Sep. 30, 2018 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK-BASED COMPENSATION Note 8: STOCK-BASED COMPENSATION The following table sets forth stock-based compensation expenses recorded during the respective periods: For the three months ended For the nine months ended September 30, September 30, 2018 2017 2018 2017 Stock Compensation expenses: Research and development $ 189,000 $ 18,700 $ 656,000 $ 56,100 General and administrative 662,000 1,667,300 1,291,000 2,276,900 Total stock compensation expenses $ 851,000 $ 1,686,000 $ 1,947,000 $ 2,333,000 At September 30, 2018, the total stock-based compensation cost related to unvested awards not yet recognized was $108,000. The expected weighted average period compensation costs to be recognized was 0.40 years. Future option grants will impact the compensation expense recognized. X - DefinitionThe entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1 GRANT INCOME 9 Months Ended Sep. 30, 2018 Grant Income [Abstract] GRANT INCOME NOTE 9: GRANT INCOME During the nine months ended September 30, 2018 and 2017, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study. In accordance with Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” issued by the Financial Accounting Standards Board, the Company recorded the $0.2 million of grant income as revenue. X - DefinitionGrant Income (Abstract) + ReferencesNo definition available. + Details Name: mrkr_GrantIncomeAbstract Namespace Prefix: mrkr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of grant income. + ReferencesNo definition available. + Details Name: mrkr_GrantIncomeTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 29 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1 SUBSEQUENT EVENT 9 Months Ended Sep. 30, 2018 Subsequent Events [Abstract] SUBSEQUENT EVENT Note 10: SUBSEQUENT EVENT The Merger On October 17, 2018, the Company completed its previously announced business combination with Marker Cell Therapy, Inc., formerly known as Marker Therapeutics, Inc., a privately-held Delaware corporation (“Marker Cell”), in accordance with the terms of an Agreement and Plan of Merger and Reorganization dated as of May 15, 2018 (the “Merger Agreement”) by and among the Company, Timberwolf Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Marker. On October 17, 2018, pursuant to the Merger Agreement, Merger Sub was merged with and into Marker Cell (the “Merger”), with Marker Cell being the surviving corporation and becoming a wholly-owned subsidiary of the Company. In connection with the Merger, the Company changed its name to Marker Therapeutics, Inc. and Marker Cell changed its name to Marker Cell Therapy, Inc. At the effective time of the Merger, the former Marker Cell stockholders received (i) an aggregate of 13,914,255 shares of the Company’s common stock which equaled the number of shares of the Company’s common stock issued and outstanding immediately prior to the effective time of the Merger, and (ii) an aggregate of 5,046,003 warrants which equaled the number of the Company’s warrants and stock options issued and outstanding immediately prior to the effective time of the Merger. The accounting for the business combination accounting is not complete. The Company is in the process of concluding on the total fair value of consideration issued and the allocation of fair value of assets acquired and liabilities assumed and therefore such information has not been concluded in these financial statements. Securities Purchase Agreements On October 17, 2018, concurrent with the completion of the Merger, the Company issued to certain accredited investors in a private placement transaction (the “Financing”), an aggregate of 17,500,000 shares of its common stock, and warrants to purchase 13,437,500 shares of common stock at an exercise price of $5.00 per share with a five-year term, for gross proceeds of $70 million pursuant to the terms of the Securities Purchase Agreements, dated June 8, 2018, by and among the Company and certain accredited investors (the “Securities Purchase Agreements”). Upon consummation of the Financing, and as a condition to the Securities Purchase Agreements, the Company is, among other things, obligated to file a resale registration statement with the SEC within 15 days following completion of the Financing. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 30 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1 SIGNIFICANT ACCOUNTING POLICIES (Policies) 9 Months Ended Sep. 30, 2018 Accounting Policies [Abstract] New Accounting Pronouncements New Accounting Pronouncement s From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption. Recent Accounting Pronouncements Adopted in the Year Compensation-Stock Compensation In May 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company adopted ASU 2017-09 on January 1, 2018; the adoption of ASU 2017-09 did not have a material impact on its financial condition or results of operations, as the Company has not had any modifications to share-based payment awards. However, if the Company does have a modification to an award in the future, it will follow the guidance in ASU 2017-09. Revenue from Contracts with Customers In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (ASU 2014-09) as modified by ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU No. 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” and ASU No. 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” The revenue recognition principle in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required. Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical expedients, or a cumulative effect upon adoption approach. The Company adopted the new standard effective January 1, 2018, using the modified retrospective approach. The only impact of the adoption of ASU 2014-09 was to reclassify the Company's grant income as revenue. Recent Accounting Pronouncements Not Yet Adopted Accounting for Certain Financial Instruments with Down Round Features On July 13, 2017, the FASB issued a two-part ASU, No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company will be evaluating the impact of adopting this standard on the consolidated financial statements and disclosures. Improvements to Non-Employee Share-Based Payment Accounting In June 2018, the FASB issued ASU 2018-07 “Improvements to Non-employee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to non-employees for goods and services. Under the ASU, most of the guidance on such payments to non-employees would be aligned with the requirements for share-based payments granted to employees. The amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new standard on its consolidated financial statements. Leases In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) which supersedes ASC Topic 840, Leases. ASU 2016-02 requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all the leases with terms greater than twelve months. Based on certain criteria, leases will be classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU No. 2018-11, “Leases (Topic 842): Targeted Improvements” that allows entities to apply the provisions of the new standard at the effective date (e.g. January 1, 2019), as opposed to the earliest period presented under the modified retrospective transition approach (January 1, 2017) and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of Topic 842, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. The Company currently expects that most of its operating lease commitments will be subject to the new standard and recognized as operating lease liabilities and right-of-use assets upon its adoption of Topic 842, which will increase the total assets and total liabilities that the Company reports relative to such amounts prior to adoption. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements. SEC Disclosure Update and Simplification In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018. The Company is evaluating the impact of this guidance on its condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 31 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1 NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) 9 Months Ended Sep. 30, 2018 Noncontrolling Interest [Abstract] Schedule of Earnings Per Share, Basic and Diluted The following table sets forth the computation of net loss per share: Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Numerator: Net loss $ (4,388,406 ) $ (3,985,510 ) $ (12,397,689 ) $ (8,298,772 ) Denominator: Weighted average common shares outstanding 13,733,406 10,219,138 12,082,176 9,081,678 Net loss per share data: Basic and Diluted $ (0.32 ) $ (0.39 ) $ (1.03 ) $ (0.91 ) Net Loss Per Share The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented: Nine Months Ended September 30, 2018 2017 Common stock options 439,000 455,000 Common stock purchase warrants 4,625,000 6,517,500 Common stock warrants - liability treatment 27,000 3,500 Potentially dilutive securities 5,091,000 6,976,000 X - DefinitionNet Loss Per Share + ReferencesNo definition available. + Details Name: mrkr_NetLossPerShareTableTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 32 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1 WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables) 9 Months Ended Sep. 30, 2018 Derivatives and Fair Value [Abstract] Valuation Methodology A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended September 30, 2018 and 2017 is as follows: September 30, September 30, 2018 2017 Stock price $ 9.05 $ 3.01 Exercise price $ 9.72 $ 1.20 Contractual term (years) 1.33 0.78 Volatility (annual) 86 % 63 % Risk-free rate 2 % 1 % Dividend yield (per share) 0 % 0 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability: Fair value measured at September 30, 2018 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) September 30, 2018 Warrant liability $ - $ - $ 107,000 $ 107,000 Fair value measured at December 31, 2017 Quoted prices in active Significant other Significant markets observable inputs unobservable inputs Fair value at (Level 1) (Level 2) (Level 3) December 31, 2017 Warrant liability $ - $ - $ 9,000 $ 9,000 Schedule of Changes in Level 3 Liabilities Measured at Fair Value The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2018: Warrant Liability Balance - December 31, 2017 $ 9,000 Change in fair value of warrant liability 98,000 Balance – September 30, 2018 $ 107,000 X - ReferencesNo definition available. + Details Name: mrkr_DerivativesAndFairValueAbstract Namespace Prefix: mrkr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFinancial assets and liabilities measured at fair value on recurring basis. + ReferencesNo definition available. + Details Name: mrkr_FinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionMeasured at fair value. + ReferencesNo definition available. + Details Name: mrkr_MeasuredAtFairValue Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionValuation methodology. + ReferencesNo definition available. + Details Name: mrkr_ValuationMethodology Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration XML 33 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCKHOLDERS' EQUITY (Tables) 9 Months Ended Sep. 30, 2018 Stockholders' Equity Note [Abstract] Schedule of weighted average valuation methodology A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows: Weighted Average Inputs Before After Modification Modification Exercise price $ 9.93 $ 2.50 Contractual term (years) 2.37 2.37 Volatility (annual) 79 % 79 % Risk-free rate 1.5 % 1.5 % Dividend yield (per share) 0 % 0 % Schedule of share purchase warrants A summary of the Company’s share purchase warrants as of September 30, 2018 and changes during the period is presented below: Weighted Average Number of Weighted Average Remaining Contractual Total Intrinsic Warrants Exercise Price Life (in years) Value Balance - January 1, 2018 6,520,000 $ 6.11 3.16 $ 1,739,000 Issued - - - - Cashless exercised (215,000 ) 4.04 - - Exercised for cash (1,497,000 ) 6.79 - - Expired or cancelled (156,000 ) 4.00 - - Balance - September 30, 2018 4,652,000 $ 6.06 2.50 $ 17,583,000 X - DefinitionTabular disclosure of share purchase warrants. + ReferencesNo definition available. + Details Name: mrkr_SharePurchaseWarrantsTableTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of valuation methodology. + ReferencesNo definition available. + Details Name: mrkr_ValuationMethodologyTableTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCK-BASED COMPENSATION (Tables) 9 Months Ended Sep. 30, 2018 Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stockbased Compensation Expenses [Table Text Block] The following table sets forth stock-based compensation expenses recorded during the respective periods: For the three months ended For the nine months ended September 30, September 30, 2018 2017 2018 2017 Stock Compensation expenses: Research and development $ 189,000 $ 18,700 $ 656,000 $ 56,100 General and administrative 662,000 1,667,300 1,291,000 2,276,900 Total stock compensation expenses $ 851,000 $ 1,686,000 $ 1,947,000 $ 2,333,000 X - DefinitionTabular disclosure of stock based compenstaion expenses recorded. + ReferencesNo definition available. + Details Name: mrkr_StockbasedCompensationExpensesTableTextBlock Namespace Prefix: mrkr_ Data Type: nonnum:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1 NATURE OF OPERATIONS - Additional Information (Detail) 1 Months Ended Oct. 17, 2018 shares Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,046,003 Subsequent Event [Member] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 17,500,000 Subsequent Event [Member] | Warrant [Member] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 13,437,500 Marker TherapeuticsInc [Member] | Subsequent Event [Member] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 13,914,255 Marker TherapeuticsInc [Member] | Subsequent Event [Member] | Warrant [Member] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,046,003 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=mrkr_MarkerTherapeuticsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 36 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1 LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) - USD ($) $ in Millions 1 Months Ended Oct. 17, 2018 Oct. 17, 2018 Sep. 30, 2018 Cash and Cash Equivalents [Line Items] Cash Equivalents, at Carrying Value $ 4.3 Class of Warrant or Right Warrants Expiration Term 5 years Subsequent Event [Member] Cash and Cash Equivalents [Line Items] Proceeds from Issuance of Private Placement $ 70.0 Private Placement [Member] | Subsequent Event [Member] Cash and Cash Equivalents [Line Items] Proceeds from Issuance of Private Placement $ 61.8 X - DefinitionPeriod of warrants, in which they are exercisable. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightWarrantsExpirationTerm Namespace Prefix: mrkr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_CashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1 NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Sep. 30, 2018 Sep. 30, 2017 Numerator: Net loss $ (4,388,406) $ (3,985,510) $ (12,397,689) $ (8,298,772) Denominator: Weighted average common shares outstanding 13,733,406 10,219,138 12,082,176 9,081,678 Net loss per share data: Basic and Diluted $ (0.32) $ (0.39) $ (1.03) $ (0.91) X - DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256 + Details Name: us-gaap_EarningsPerShareBasicAndDiluted Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAttributableToParentDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 38 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1 NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) - shares 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Potentially dilutive securities 5,091,000 6,976,000 Employee Stock Option [Member] Potentially dilutive securities 439,000 455,000 Warrant [Member] Potentially dilutive securities 4,625,000 6,517,500 Common Stock Warrants Liability Treatment [Member] Potentially dilutive securities 27,000 3,500 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mrkr_CommonStockWarrantsLiabilityTreatmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1 WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] Sep. 30, 2018 $ / shares Sep. 30, 2017 $ / shares Measurement Input, Share Price [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Stock price $ 9.05 $ 3.01 Measurement Input, Exercise Price [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 9.72 1.20 Measurement Input, Expected Term [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Term 1 year 3 months 29 days 9 months 11 days Measurement Input, Price Volatility [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 86 63 Measurement Input, Risk Free Interest Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 2 1 Measurement Input, Expected Dividend Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 0 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=mrkr_SharePurchaseWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1 WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) Sep. 30, 2018 Dec. 31, 2017 Quoted prices in active markets (Level 1) Derivatives, Fair Value [Line Items] Warrant liability $ 0 $ 0 Significant other observable inputs (Level 2) Derivatives, Fair Value [Line Items] Warrant liability 0 0 Significant other unobservable inputs (Level 3) Derivatives, Fair Value [Line Items] Warrant liability 107,000 9,000 Fair value Derivatives, Fair Value [Line Items] Warrant liability $ 107,000 $ 9,000 X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313 + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1 WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) 9 Months Ended Sep. 30, 2018 USD ($) Class of Warrant or Right [Line Items] Balance $ 9,000 Change in fair value of warrant liability 98,000 Balance $ 107,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 42 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCKHOLDERS' EQUITY - Weighted average summary of quantitative information (Detail) - Share Purchase Warrants [Member] Sep. 30, 2018 Sep. 30, 2017 Measurement Input, Exercise Price [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 9.72 1.20 Measurement Input, Expected Term [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Term 1 year 3 months 29 days 9 months 11 days Measurement Input, Price Volatility [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 86 63 Measurement Input, Risk Free Interest Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 2 1 Measurement Input, Expected Dividend Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 0 0 Weighted Average Inputs Before Modification [Member] | Measurement Input, Exercise Price [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 9.93 Weighted Average Inputs Before Modification [Member] | Measurement Input, Expected Term [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Term 2 years 4 months 13 days Weighted Average Inputs Before Modification [Member] | Measurement Input, Price Volatility [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 79 Weighted Average Inputs Before Modification [Member] | Measurement Input, Risk Free Interest Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 1.5 Weighted Average Inputs Before Modification [Member] | Measurement Input, Expected Dividend Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 0 Weighted Average Inputs After Modification [Member] | Measurement Input, Exercise Price [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 2.50 Weighted Average Inputs After Modification [Member] | Measurement Input, Expected Term [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Term 2 years 4 months 13 days Weighted Average Inputs After Modification [Member] | Measurement Input, Price Volatility [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 79 Weighted Average Inputs After Modification [Member] | Measurement Input, Risk Free Interest Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 1.5 Weighted Average Inputs After Modification [Member] | Measurement Input, Expected Dividend Rate [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Warrants and Rights Outstanding, Measurement Input 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=mrkr_SharePurchaseWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mrkr_WeightedAverageInputsBeforeModificationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mrkr_WeightedAverageInputsAfterModificationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCKHOLDERS' EQUITY- Summary of the Company's share purchase warrants (Detail) - USD ($) 9 Months Ended 12 Months Ended Sep. 30, 2018 Dec. 31, 2017 Number of Warrants, Beginning balance 6,520,000 Number of Warrants, Issued 0 Number of Warrant of Cashless exercised (215,000) Number of Warrant Exercised for cash (1,497,000) Number of Warrant Expired or Cancelled (156,000) Number of Warrants, Ending balance 4,652,000 6,520,000 Weighted Average Exercise Price, Beginning Balance $ 6.11 Weighted Average Exercise Price, Issued 0 Weighted Average Exercise Price Cashless exercised 4.04 Weighted Average Exercise Price, Exercised for cash 6.79 Weighted Average Exercise Price Expired or Cancelled 4.00 Weighted Average Exercise Price, Ending Balance $ 6.06 $ 6.11 Weighted Average Remaining Contractual Life, Outstanding (in years) 2 years 6 months 3 years 1 month 28 days Total Intrinsic Value $ 17,583,000 $ 1,739,000 X - DefinitionIntrinsic value of outstanding class of warrant or right. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightOutStandingIntrinsicValue Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionClass of warrant or rights outstanding issued weighted average exercise price. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutStandingIssuedWeightedAverageExercisePrice Namespace Prefix: mrkr_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass Of Warrant Or Rights Outstanding Weighted Average Exercise Price. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutStandingWeightedAverageExercisePrice Namespace Prefix: mrkr_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionClass of warrant or right outstanding issued weighted average remaining life. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutStandingWeightedAverageRemainingContractualLife Namespace Prefix: mrkr_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or rights outstanding cashless exercised weighted average exercise price. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutstandingCashlessExercisedWeightedAverageExercisePrice Namespace Prefix: mrkr_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or rights outstanding exercised weighted average exercise price. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutstandingExercisedWeightedAverageExercisedForCash Namespace Prefix: mrkr_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionClass of warrant or rights outstanding expired or Cancelled weighted average exercise price. + ReferencesNo definition available. + Details Name: mrkr_ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice Namespace Prefix: mrkr_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants exercised. + ReferencesNo definition available. + Details Name: mrkr_NumberOfWarrantExercisedForCash Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants expired or cancelled. + ReferencesNo definition available. + Details Name: mrkr_NumberOfWarrantExpiredOrCancelled Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants issued. + ReferencesNo definition available. + Details Name: mrkr_NumberOfWarrantIssued Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants cashless exercised. + ReferencesNo definition available. + Details Name: mrkr_NumberOfWarrantsCashlessExercised Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 44 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCKHOLDERS' EQUITY - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 9 Months Ended May 14, 2018 Jan. 31, 2018 Sep. 30, 2018 Sep. 30, 2017 Sep. 30, 2018 Sep. 30, 2017 Common Stock Capital Shares Reserved For Future Issuance [Line Items] Stock Issued During Period, Shares, New Issues 1,300,000 Shares Issued, Price Per Share $ 2.50 Stock Issued During Period, Value, New Issues $ 3,120,000 Class of Warrant or Right, Number of Securities Called by Warrants or Rights 782,505 Proceeds from Warrant Exercises $ 2,000,000 $ 4,344,171 $ 619,623 Exercise Of Warrants Amount 4,344,171 Non Cash Excercise Of Warrants Amount $ 215 0 Number Of Warrant Expired or Cancelled (156,000) Research and Development Expense $ 1,877,260 $ 1,623,302 $ 5,303,647 $ 3,815,119 Consulting Arrangements [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Allocated Share-based Compensation Expense 206,446 Selling, General and Administrative Expense 1,300,000 Research and Development Expense $ 1,200,000 Stock Issued During Period, Shares, Issued for Services 100,000 Warrant [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Exercise Of Warrants Amount $ 728,000 Eastern Capital Limited [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Shares Issued, Price Per Share $ 2.40 Exercise Of Stock Warrants [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights 930,000 930,000 Proceeds from Warrant Exercises $ 2,400,000 Non Cash Excercise Of Warrants Amount $ 152,588 Number Of Warrant Expired or Cancelled 215,344 Common Stock [Member] Common Stock Capital Shares Reserved For Future Issuance [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 10,416 10,416 Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price $ 1.74 Exercise Of Warrants Amount $ 1,497 X - DefinitionCommon Stock Capital Shares Reserved For Future Issuance [Line Items] + ReferencesNo definition available. + Details Name: mrkr_CommonStockCapitalSharesReservedForFutureIssuanceLineItems Namespace Prefix: mrkr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise of warrants amount. + ReferencesNo definition available. + Details Name: mrkr_ExerciseOfWarrantsAmount Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of warrant exercised of non cash amount transaction. + ReferencesNo definition available. + Details Name: mrkr_NonCashExcerciseOfWarrantsAmount Namespace Prefix: mrkr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of warrants expired or cancelled. + ReferencesNo definition available. + Details Name: mrkr_NumberOfWarrantExpiredOrCancelled Namespace Prefix: mrkr_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: mrkr_ArrangementsAxis=mrkr_ConsultingArrangementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mrkr_EasternCapitalLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=mrkr_ExerciseOfStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCK-BASED COMPENSATION (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Sep. 30, 2018 Sep. 30, 2017 Share-based Compensation [Abstract] Share-based Compensation $ 851,000 $ 1,686,000 $ 1,947,733 $ 2,332,915 Research and Development Expense [Member] Share-based Compensation [Abstract] Share-based Compensation 189,000 18,700 656,000 56,100 General and Administrative Expense [Member] Share-based Compensation [Abstract] Share-based Compensation $ 662,000 $ 1,667,300 $ 1,291,000 $ 2,276,900 X - DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1 STOCK-BASED COMPENSATION - Additional Information (Detail) 9 Months Ended Sep. 30, 2018 USD ($) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized $ 108,000 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition 4 months 24 days X - DefinitionUnrecognized cost of unvested share-based compensation awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (i) -URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 47 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1 GRANT INCOME - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2018 Sep. 30, 2017 Sep. 30, 2018 Sep. 30, 2017 Revenues $ 0 $ 183,064 $ 205,994 $ 183,064 Grant [Member] Revenues $ 0 $ 183,064 205,994 $ 183,064 Accounting Standards Update 2014-09 [Member] Revenues $ 200,000 X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_GrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1 SUBSEQUENT EVENTS - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended Oct. 17, 2018 May 14, 2018 Class of warrant or right, number of securities called by warrants or rights | shares 782,505 Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 5,046,003 Subsequent Event [Member] Class of warrant or right, number of securities called by warrants or rights | shares 13,914,255 Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 17,500,000 Proceeds from Issuance of Private Placement $ 70 Subsequent Event [Member] | Warrant [Member] Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 13,437,500 Class of Warrant or Right, Exercise Price of Warrants or Rights $ 5.00 X - DefinitionNumber of shares of equity interests issued or issuable to acquire entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: num:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 89 126 1 false 33 0 false 4 false false R1.htm 1001 - Document - Document And Entity Information Sheet http://www.tapimmune.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.tapimmune.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementOfStockholdersEquity CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.tapimmune.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 1007 - Disclosure - NATURE OF OPERATIONS Sheet http://www.tapimmune.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 1008 - Disclosure - BASIS OF PRESENTATION Sheet http://www.tapimmune.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 1009 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION Sheet http://www.tapimmune.com/role/LiquidityAndFinancialCondition LIQUIDITY AND FINANCIAL CONDITION Notes 9 false false R10.htm 1010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.tapimmune.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 1011 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Sheet http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholder NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER Notes 11 false false R12.htm 1012 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS Sheet http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 1013 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.tapimmune.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 1014 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.tapimmune.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 14 false false R15.htm 1015 - Disclosure - GRANT INCOME Sheet http://www.tapimmune.com/role/GrantIncome GRANT INCOME Notes 15 false false R16.htm 1016 - Disclosure - SUBSEQUENT EVENT Sheet http://www.tapimmune.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 16 false false R17.htm 1017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.tapimmune.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 1018 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) Sheet http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderTables NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER (Tables) Tables http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholder 18 false false R19.htm 1019 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsTables WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurements 19 false false R20.htm 1020 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.tapimmune.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.tapimmune.com/role/StockholdersEquity 20 false false R21.htm 1021 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.tapimmune.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.tapimmune.com/role/StockBasedCompensation 21 false false R22.htm 1022 - Disclosure - NATURE OF OPERATIONS - Additional Information (Detail) Sheet http://www.tapimmune.com/role/NatureOfOperationsAdditionalInformationDetail NATURE OF OPERATIONS - Additional Information (Detail) Details 22 false false R23.htm 1023 - Disclosure - LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) Sheet http://www.tapimmune.com/role/LiquidityAndFinancialConditionAdditionalInformationDetail LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) Details 23 false false R24.htm 1024 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) Sheet http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderComputationOfIncomeLossPerShareDetail NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Computation of income (loss) per share (Detail) Details 24 false false R25.htm 1025 - Disclosure - NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) Sheet http://www.tapimmune.com/role/NetLossPerShareApplicableToCommonShareholderPotentiallyDilutiveSecuritiesDetail NET LOSS PER SHARE APPLICABLE TO COMMON SHAREHOLDER - Potentially Dilutive Securities (Detail) Details 25 false false R26.htm 1026 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) Sheet http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionValuationMethodologyDetail WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) Details 26 false false R27.htm 1027 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 27 false false R28.htm 1028 - Disclosure - WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) Sheet http://www.tapimmune.com/role/WarrantLiabilityAndFairValueMeasurementsConversionOptionScheduleOfChangesInLevel3LiabilitiesMeasuredAtFairValueDetail WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail) Details 28 false false R29.htm 1029 - Disclosure - STOCKHOLDERS' EQUITY - Weighted average summary of quantitative information (Detail) Sheet http://www.tapimmune.com/role/StockholdersEquityWeightedAverageSummaryOfQuantitativeInformationDetail STOCKHOLDERS' EQUITY - Weighted average summary of quantitative information (Detail) Details 29 false false R30.htm 1030 - Disclosure - STOCKHOLDERS' EQUITY- Summary of the Company's share purchase warrants (Detail) Sheet http://www.tapimmune.com/role/StockholdersEquitySummaryOfTheCompanySSharePurchaseWarrantsDetail STOCKHOLDERS' EQUITY- Summary of the Company's share purchase warrants (Detail) Details 30 false false R31.htm 1031 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Detail) Sheet http://www.tapimmune.com/role/StockholdersEquityAdditionalInformationDetail STOCKHOLDERS' EQUITY - Additional Information (Detail) Details 31 false false R32.htm 1032 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.tapimmune.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.tapimmune.com/role/StockBasedCompensationTables 32 false false R33.htm 1033 - Disclosure - STOCK-BASED COMPENSATION - Additional Information (Detail) Sheet http://www.tapimmune.com/role/StockBasedCompensationAdditionalInformationDetail STOCK-BASED COMPENSATION - Additional Information (Detail) Details 33 false false R34.htm 1034 - Disclosure - GRANT INCOME - Additional Information (Detail) Sheet http://www.tapimmune.com/role/GrantIncomeAdditionalInformationDetail GRANT INCOME - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - SUBSEQUENT EVENTS - Additional Information (Detail) Sheet http://www.tapimmune.com/role/SubsequentEventsAdditionalInformationDetail SUBSEQUENT EVENTS - Additional Information (Detail) Details 35 false false All Reports Book All Reports mrkr-20180930.xml mrkr-20180930.xsd mrkr-20180930_cal.xml mrkr-20180930_def.xml mrkr-20180930_lab.xml mrkr-20180930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 55 0001144204-18-059353-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-059353-xbrl.zip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

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 08, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Registrant Name	Marker Therapeutics, Inc.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	MRKR
Entity Common Stock, Shares Outstanding		45,370,695
Entity Emerging Growth Company	false
Entity Small Business	true

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 4,294,271	$ 5,129,289
Prepaid expenses and deposits	96,967	51,150
Total current assets	4,391,238	5,180,439
Total assets	4,391,238	5,180,439
Current liabilities:
Accounts payable and accrued liabilities	3,588,771	1,508,312
Warrant liability	107,000	9,000
Promissory note	5,000	5,000
Total current liabilities	3,700,771	1,522,312
Total liabilities	3,700,771	1,522,312
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41.7 million shares authorized, 13.8 million and 10.6 million shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively	13,845	10,616
Additional paid-in capital	171,221,851	161,067,538
Accumulated deficit	(170,545,229)	(157,420,027)
Total stockholders' equity	690,467	3,658,127
Total liabilities and stockholders' equity	4,391,238	5,180,439
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,700,000	41,700,000
Common stock shares issued	13,800,000	10,600,000
Common stock shares outstanding	13,800,000	10,600,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenues	$ 0	$ 183,064	$ 205,994	$ 183,064
Operating expenses:
Research and development	1,877,260	1,623,302	5,303,647	3,815,119
General and administrative	2,551,146	2,549,272	7,202,036	5,167,582
Total operating expenses	4,428,406	4,172,574	12,505,683	8,982,701
Loss from operations	(4,428,406)	(3,989,510)	(12,299,689)	(8,799,637)
Other income (expense):
Change in fair value of warrant liabilities	40,000	4,000	(98,000)	8,500
Debt extinguishment gain	0	0	0	492,365
Net loss	$ (4,388,406)	$ (3,985,510)	$ (12,397,689)	$ (8,298,772)
Net loss per share, Basic and Diluted	$ (0.32)	$ (0.39)	$ (1.03)	$ (0.91)
Weighted average number of common shares outstanding	13,733,406	10,219,138	12,082,176	9,081,678
Grant [Member]
Revenues:
Total revenues	$ 0	$ 183,064	$ 205,994	$ 183,064

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Balance, Amount at Dec. 31, 2017	$ 3,658,127	$ 10,616	$ 161,067,538	$ (157,420,027)
Balance, Share at Dec. 31, 2017		10,615,724
Issuance of common stock in private placement, Amount	3,120,000	$ 1,300	3,118,700	0
Issuance of common stock in private placement, Share		1,300,000
Stock options exercised for cash, Amount	18,125	$ 10	18,115	0
Stock options exercised for cash, Share		10,416
Stock warrants exercised for cash, Amount	4,344,171	$ 1,497	4,342,674	0
Stock warrants exercised for cash, Share		1,496,881
Stock warrants cashless exercised, Amount	0	$ 215	(215)	0
Stock warrants cashless exercised, Share		215,336
Stock-based compensation, Amount	1,947,733	$ 207	1,947,526	0
Stock-based compensation, Share		206,446
Fair value of repriced warrants as inducement	0	$ 0	727,513	(727,513)
Net loss	(12,397,689)	0	0	(12,397,689)
Balance, Amount at Sep. 30, 2018	$ 690,467	$ 13,845	$ 171,221,851	$ (170,545,229)
Balance, Share at Sep. 30, 2018		13,844,803

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Operating Activities:
Net loss	$ (12,397,689)	$ (8,298,772)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	98,000	(8,500)
Stock-based compensation	1,947,733	2,332,915
Debt extinguishment gain	0	(492,365)
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(45,817)	(26,381)
Accounts payable and accrued expenses	2,080,459	532,122
Net cash used in operating activities	(8,317,314)	(5,960,981)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	3,120,000	5,408,343
Proceeds from exercise of stock warrants, net of offering costs	4,344,171	619,623
Proceeds from exercise of stock options	18,125	0
Repurchase of common stock to pay for employee withholding taxes	0	(310,493)
Net cash provided by financing activities	7,482,296	5,717,473
Net decrease in cash	(835,018)	(243,508)
Cash at beginning of period	5,129,289	7,851,243
Cash at end of period	4,294,271	7,607,735
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	727,513	622,042
Stock warrants cashless exercised	$ 215	$ 0

NATURE OF OPERATIONS - Additional Information (Detail)	1 Months Ended
NATURE OF OPERATIONS - Additional Information (Detail)	Oct. 17, 2018 shares
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,046,003
Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	17,500,000
Subsequent Event [Member] \| Warrant [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	13,437,500
Marker TherapeuticsInc [Member] \| Subsequent Event [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	13,914,255
Marker TherapeuticsInc [Member] \| Subsequent Event [Member] \| Warrant [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,046,003

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended
	Oct. 17, 2018	Oct. 17, 2018	Sep. 30, 2018
Cash and Cash Equivalents [Line Items]
Cash Equivalents, at Carrying Value			$ 4.3
Class of Warrant or Right Warrants Expiration Term	5 years
Subsequent Event [Member]
Cash and Cash Equivalents [Line Items]
Proceeds from Issuance of Private Placement		$ 70.0
Private Placement [Member] \| Subsequent Event [Member]
Cash and Cash Equivalents [Line Items]
Proceeds from Issuance of Private Placement	$ 61.8

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]	Sep. 30, 2018 $ / shares	Sep. 30, 2017 $ / shares
Measurement Input, Share Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 9.05	$ 3.01
Measurement Input, Exercise Price [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	9.72	1.20
Measurement Input, Expected Term [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Term	1 year 3 months 29 days	9 months 11 days
Measurement Input, Price Volatility [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	86	63
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	2	1
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	0	0

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Warrant liability	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Warrant liability	0	0
Significant other unobservable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Warrant liability	107,000	9,000
Fair value
Derivatives, Fair Value [Line Items]
Warrant liability	$ 107,000	$ 9,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	9 Months Ended
	Sep. 30, 2018 USD ($)
Class of Warrant or Right [Line Items]
Balance	$ 9,000
Change in fair value of warrant liability	98,000
Balance	$ 107,000

STOCKHOLDERS' EQUITY- Summary of the Company's share purchase warrants (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Warrants, Beginning balance	6,520,000
Number of Warrants, Issued	0
Number of Warrant of Cashless exercised	(215,000)
Number of Warrant Exercised for cash	(1,497,000)
Number of Warrant Expired or Cancelled	(156,000)
Number of Warrants, Ending balance	4,652,000	6,520,000
Weighted Average Exercise Price, Beginning Balance	$ 6.11
Weighted Average Exercise Price, Issued	0
Weighted Average Exercise Price Cashless exercised	4.04
Weighted Average Exercise Price, Exercised for cash	6.79
Weighted Average Exercise Price Expired or Cancelled	4.00
Weighted Average Exercise Price, Ending Balance	$ 6.06	$ 6.11
Weighted Average Remaining Contractual Life, Outstanding (in years)	2 years 6 months	3 years 1 month 28 days
Total Intrinsic Value	$ 17,583,000	$ 1,739,000

STOCKHOLDERS' EQUITY - Additional Information (Detail) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	May 14, 2018	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, New Issues	1,300,000
Shares Issued, Price Per Share	$ 2.50
Stock Issued During Period, Value, New Issues	$ 3,120,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	782,505
Proceeds from Warrant Exercises	$ 2,000,000				$ 4,344,171	$ 619,623
Exercise Of Warrants Amount					4,344,171
Non Cash Excercise Of Warrants Amount					$ 215	0
Number Of Warrant Expired or Cancelled					(156,000)
Research and Development Expense			$ 1,877,260	$ 1,623,302	$ 5,303,647	$ 3,815,119
Consulting Arrangements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Allocated Share-based Compensation Expense					206,446
Selling, General and Administrative Expense					1,300,000
Research and Development Expense					$ 1,200,000
Stock Issued During Period, Shares, Issued for Services					100,000
Warrant [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Exercise Of Warrants Amount					$ 728,000
Eastern Capital Limited [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Shares Issued, Price Per Share	$ 2.40
Exercise Of Stock Warrants [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			930,000		930,000
Proceeds from Warrant Exercises					$ 2,400,000
Non Cash Excercise Of Warrants Amount					$ 152,588
Number Of Warrant Expired or Cancelled					215,344
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		10,416			10,416
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 1.74
Exercise Of Warrants Amount					$ 1,497

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation [Abstract]
Share-based Compensation	$ 851,000	$ 1,686,000	$ 1,947,733	$ 2,332,915
Research and Development Expense [Member]
Share-based Compensation [Abstract]
Share-based Compensation	189,000	18,700	656,000	56,100
General and Administrative Expense [Member]
Share-based Compensation [Abstract]
Share-based Compensation	$ 662,000	$ 1,667,300	$ 1,291,000	$ 2,276,900

STOCK-BASED COMPENSATION - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018 USD ($)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 108,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	4 months 24 days